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ABSTRACT 
Breast cancer is the second most common cancer and the second leading cause of cancer-related 
death among women.   The current project examined some key issues important for effective 
breast cancer management in the Medicaid population.  Medicaid is one the largest healthcare 
insurance systems in the US providing coverage to more than 60 million low-income individuals.  
As a part of this project, three studies were conducted.  The first study determined the healthcare 
burden associated with breast cancer in the form of healthcare use (inpatient, outpatient, and 
emergency room [ER] visits) and costs associated with the condition in the Medicaid population.  
Significant healthcare burden was observed as the all-cause inpatient, outpatient, and ER visits 
and the total all-cause costs were found to be significantly higher among women with breast 
cancer as compared to women without breast cancer.  The second study determined the impact of 
pre-existing mental illness on guideline-consistent breast cancer treatment and breast cancer-
related healthcare use among Medicaid enrollees diagnosed with breast cancer.  Negative 
association was observed between pre-existing mental illness and guideline-consistent breast 
cancer treatment and breast cancer-related outpatient visits indicating treatment disparities 
among women with breast cancer with pre-existing mental illnesses.  The third study determined 
factors associated with repeat mammography screening in the Medicaid population.  Recipient 
characteristics including age, race, number of outpatient visits during the study period, number of 
emergency room visits during the study period, use of hormone replacement therapy, and routine 
cervical cancer screening significantly impacted receipt of repeat mammography screening.  The 
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findings of this project could be useful to Medicaid program planners in designing strategies 
aimed at reducing disparities in breast cancer-related healthcare in the Medicaid population.  
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CHAPTER 1 
INTRODUCTION 
Overview of breast cancer 
Breast cancer is defined as the uncontrolled or abnormal growth of cells within the breast.  It is 
one of the oldest forms of cancer in humans, with records of breast cancer cases dating back to 
1600 BC (Russo and Russo, 1995).  The known risk factors for breast cancer include early age at 
menarche, late age at menopause and first child birth, family history of breast cancer, benign 
breast disease, use of hormone replacement therapy, nulliparity, physical inactivity, poverty, 
inadequate education, alcohol intake, and lack of health insurance (Gail et al., 1989, Lambe et 
al., 1996, Burke et al., 1997, Collaborative Group on Hormonal Factors in Breast Cancer, 1997, 
Smith-Warner et al., 1998, Grenall and Wood, 2000, Chlebowski et al., 2003, Buchholz, 2009).  
Symptoms of breast cancer include breast lump, breast swelling or thickening, breast skin 
irritation, flakiness or redness around the nipple, blood discharge from nipple, breast size change, 
and pain in the breast (Osteen, 2001).  
 
Types of breast cancer 
Breast cancer is generally categorized in terms of its histology, hormone receptor status, and 
expression of tumor markers.  In terms of tumor histology, the two most common types of breast 
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cancer are ductal carcinoma and lobular carcinoma.  The ductal carcinomas start inside the milk 
ducts in the breast.  The lobular carcinomas start in the lobules, which are the milk producing  
glands present at the end of milk ducts.  Each of these can be subdivided into non-invasive 
carcinomas (in situ), which remain confined to the point of origin, and invasive carcinomas, 
which spread to the other tissues of the breast.  The ductal and lobular carcinomas together 
account for 90% of the breast cancer cases (Li et al., 2005).  Other less common histological 
types of breast cancer include inflammatory breast cancer, Paget’s disease of the nipple, and 
phyllodes tumor.  Inflammatory breast cancers involve reddening and swelling of the breast 
rather than presence of an observable lump.  In Paget’s disease of the nipple, the cancer cells 
develop in and around the nipple.  Phyllodes tumors start in the connective tissue of the breast.  
Based on the presence of receptors for hormones estrogen and progesterone on the breast cancer 
cells, breast cancers can be classified as estrogen or progesterone receptor (ER/PR) positive or 
negative.  Presence of tumor markers such as human epidermal growth factor 2 (HER2), 
carcinoma antigen (CA) 15-3, CA 27.29, carcinoembryonic antigen (CEA), urokinase 
plasminogen activator (uPA), and plasminogen activator inhibitor (PAI-1) in blood or urine is 
also used to classify breast cancer (Li et al., 2005). 
 
Stages of breast cancer 
The extent of breast cancer at the time of diagnosis is codified using breast cancer staging 
systems.  The most commonly used breast cancer staging system among clinicians is the primary 
tumor, regional lymph nodes, and distant metastases (TNM) system developed by the American 
Joint Committee on Cancer (AJCC).  The TNM system classifies breast cancer into stages 0 to 
IV in the order of increasing severity.  In stage 0, cancer cells are still within the ducts or lobules 
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and have not spread to the surrounding fatty breast tissue or to lymph nodes.  Stage I is further 
classified into IA and IB.  In stage IA, the size of the tumor is equal or less than 2 centimeters 
(cm) and the tumor is restricted within the breast.  In stage IB, small clusters of breast cancer 
cells are found in the lymph nodes with no tumor or a tumor 2 cm or smaller in the breast.  Stage 
II breast cancer is also classified into IIA and IIB.  Stage IIA is characterized by presence of 
breast cancer in the lymph nodes with no tumor or a tumor 2 cm or smaller in the breast or a 
tumor 2-5 cm in size in the breast that has not spread to the lymph nodes.  In stage IIB, the tumor 
is 2-5 cm in size and has spread to 1 to 3 axillary lymph nodes or to lymph nodes surrounding the 
breastbone, or the tumor is greater than 5 cm and the spread has not occured to the lymph nodes.  
Stage III breast cancer consists of subcategories of stage IIIA, IIIB, and IIIC.  In stage IIIA, the 
tumor is greater than 5 cm in size and has spread to 1 to 3 axillary lymph nodes or lymph nodes 
surrounding the breastbone, or the tumor is not present in the breast, but is present in 4-9 axillary 
lymph nodes or lymph nodes near the breastbone.  Stage IIIB cancer is characterized by tumor 
that has spread to the chest wall or the skin of the breast and up to 9 axillary lymph nodes or 
lymph nodes surrounding the breastbone, with presence of a swelling or ulcer.  In stage IIIC, the 
cancer has spread to the chest wall or the skin of the breast and 10 or more axillary lymph nodes 
or lymph nodes surrounding the breastbone or those above or below the collar bone, with 
presence of a swelling or ulcer.  Stage IV is the terminal stage of breast cancer in which the 
cancer has spread to the other organs of the body such as bones, lungs, liver, or the brain 
(Flemming et al., 1997, National Cancer Institute). 
 
Occurrence of breast cancer in the US 
4 
 
The incidence rates of breast cancer in the US rose significantly between 1930s and 1990s (Glass 
and Hoover, 1988, Glass et al., 2007).  The increase in breast cancer incidence during this period 
was attributed to various factors, including change in reproductive profiles of women, 
introduction of mammography screening, and increasing use of hormone replacement therapy 
(HRT) for the treatment of menopause (Feuer and Wun, 1992, Glass et al., 2007).  The breast 
cancer incidence rates declined in the early 2000s (Glass et al., 2007, Jemal et al., 2007, Ravdin 
et al., 2007).  It has been argued that the principal factor behind this decline is the reduction in 
the use of HRT due to the Women’s Health Initiative report, which suggested an association 
between long term use of HRT and breast cancer (Clarke et al., 2006).  The decline in 
mammography screening rates in the early 2000s has also been considered as a contributing 
factor to the decrease in the breast cancer incidence rates (Breen et al., 2007, Glass et al., 2007).  
The breast cancer incidence rates have been found to be stable post the decline observed in the 
early 2000s (Glass et al., 2007, DeSantis et al., 2011).   
The prevalence of breast cancer has increased over the years due to factors such as 
improvement in breast cancer treatment and early detection of breast cancer owing to increased 
mammography screening rates (Alacacioglu et al., 2009, Breast cancer facts and figures 2011-
2012).  There were nearly 3 million breast cancer survivors in the US as of January 01, 2012.  
The number of women with breast cancer is expected to increase to nearly 3.8 million by the 
calendar year 2022 (Siegel et al., 2012). 
 
Economic burden of breast cancer 
Breast cancer is associated with a significant economic burden.  The healthcare costs in patients 
with breast cancer have been found to be significantly higher than those in patients with other 
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ailments (Sasser et al., 2005, Barron et al., 2008, Fu et al., 2012).  In their study involving 
beneficiaries of five managed care plans in the US, Barron et al. (2008) found average monthly 
all-cause direct medical costs of $4,421 in patients with breast cancer as compared to $3,352 in 
patients with other ailments.  The costs of treatment of breast cancer vary by treatment phase.  In 
general, the per unit time costs incurred during terminal phase are higher than those incurred 
during initial and continuing phases (Fireman et al., 1997, Warren et al., 2002).  In a study 
involving breast cancer patients enrolled in Kaiser Permanante medical care program during 
1987-1991, Fireman et al. (1997) found the six-monthly costs of initial, continuing, and terminal 
care to be $14,737, $2,245, and $18,406 respectively.  Continuing care accounts for the greatest 
proportion of the lifetime costs due to high survival rates of breast cancer patients (Mariotto et al, 
2011).  The lifetime per patient direct medical costs of breast cancer have been estimated to be 
between $20,000 and $100,000 (Baker et al., 1991, Barnett et al., 1997, Lamerato et al., 2006, 
Campbell et al., 2009).  The total national annual treatment costs of breast cancer in the US have 
been estimated to be roughly $16.5 billion (Mariotto et al., 2011).  The annual lost productivity 
costs of breast cancer in the US have been reported to be nearly $11 billion (Bradley et al., 
2008).  
 
Treatment of breast cancer 
The treatment of breast cancer has improved significantly over the last couple of decades (ACS).  
Existing treatment modes for breast cancer include surgery, radiation therapy, and adjuvant 
systemic therapies such as chemotherapy, endocrine therapy, and targeted therapy.  Surgery is 
the primary mode of treatment for breast cancer.  Some of the aggressive surgical breast cancer 
therapies include radical mastectomy, modified radical mastectomy, and total mastectomy.  
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Radical mastectomy consists of removal of the whole breast, the lymph nodes, and the skin 
overlying the breast, whereas modified radical mastectomy involves removal of the whole breast 
that has cancer and many of the lymph nodes under the arm.  Total mastectomy consists of 
removal of the whole breast that has cancer but not the auxiliary body parts.  A relatively less 
aggressive surgical breast cancer treatment regimen is breast-conserving surgery, a procedure 
performed to remove the cancer but not the breast itself.  Examples of breast conserving surgery 
include lumpectomy, quadrantectomy, and segmental mastectomy.  While lumpectomy involves 
removal of the tumor lump in the breast, quadrantectomy consists of removal of one quarter of 
the breast.  Segmental mastectomy involves removal of the tumor, the surrounding breast tissue, 
and the lining over the chest muscles below the tumor.  Radiation therapy involves the use of 
high-energy x-rays or gamma rays to kill the cancer cells or keep them from growing (NCI).   
Radical mastectomy was the standard of breast cancer surgical care until the 1960s 
(Pilnik, 2003).  However, several randomized controlled studies conducted to evaluate the 
effectiveness of various breast cancer treatment regimens have shown that survival in breast 
cancer is not associated with the aggressiveness of the local therapy.  The National Surgical 
Adjuvant Breast and Bowel Project (NSABP) B-04 randomized controlled trial, which involved 
patients with operable node negative breast cancer in the US and Canada, found no significant 
differences in long term survival among patients undergoing radical mastectomy, total 
mastectomy, or total mastectomy with adjuvant radiotherapy (Fisher et al., 2006).  The NSABP 
B-06 trial compared the effectiveness of total mastectomy alone, lumpectomy plus axillary 
lymph node dissection, and lumpectomy with axillary lymph node dissection and radiation 
therapy.  No significant differences were observed in terms of disease-free and overall survival 
between the three treatment regimens.  However, an additional benefit of radiation therapy was 
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observed in the study with reduced instances of locoregional recurrence observed in patients 
undergoing lumpectomy with axillary lymph node dissection and radiation therapy as compared 
to those undergoing lumpectomy and axillary lymph node dissection (3% vs. 9%) (Fisher et al., 
2002).  Overgaard et al (1997) studied the effect of radiation therapy after mastectomy and 
adjuvant chemotherapy in premenopausal women with stage II or III breast cancer.  Post-
mastectomy radiation therapy was associated with 23% reduction in locoregional recurrence and 
9% improvement in overall survival.  In a similar study, Overgaard et al. (1999) observed 27% 
reduction in locoregional recurrence, 12% improvement in disease-free survival, and 9% 
improvement in overall survival due to use of radiation therapy after mastectomy in 
postmenopausal women with stage II or III breast cancer.  A meta-analysis of 78 randomized 
controlled trials conducted by Clarke et al. (2005) revealed that use of radiotherapy post breast 
conserving surgery or mastectomy was associated with a nearly 20% reduction in locoregional 
recurrence and 5% reduction in breast cancer-specific mortality.  Owing to findings from such 
studies, breast conserving surgery with radiation therapy or total mastectomy is currently the 
recommended primary treatment regimen for breast cancer (NIH guidelines for the treatment of 
breast cancer, 1990, National Comprehensive Cancer Network [NCCN], 2006, Maughan et al., 
2011).  Post-mastectomy radiation therapy is recommended in patients with tumors five 
centimeters (cm) or more in size or tumors that have spread to four or more axillary lymph nodes 
(NCCN, 2006, Maughan et al., 2011). 
  Systemic adjuvant therapies such as chemotherapy, endocrine therapy, and tissue-
targeted therapy are crucial for preventing the growth of existing tumor, reducing the recurrence 
rate, and improving breast cancer-specific survival.  The choice of systemic adjuvant therapies 
depends on hormone receptor status, menopausal status, HER2 expression, and lymph node 
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involvement.  Consensus guidelines recommend chemotherapies in patients with lymph node 
node-positive breast cancer or those with tumors larger than 1 cm (NCCN, 2006, Maughan et al., 
2011).  It has been reported that chemotherapies are more beneficial in hormone receptor-
negative breast cancers as compared to hormone receptor-positive breast cancers (Goldhirsch et 
al., 2007).  Induction chemotherapy aimed at reducing the tumor size is generally administered 
prior to surgery in stage III breast cancer patients.  Some of the common chemotherapy drugs 
include anthracyclines (e.g., doxorubicin and epirubicin), taxanes (e.g., docetaxel and paclitaxel), 
cyclophosphamide, and capecitabine.  Taxanes and anthracyclines are the preferred 
chemotherapy drugs since lower cancer recurrence rates and higher disease-specific survival 
have been observed in patients on anthracycline or taxane regimens as compared to other 
chemotherapy drugs (Maughan et al., 2011).  In addition, use of anthracycline and taxane has 
been associated with higher disease-specific and overall survival as compared to use of 
anthracycline only (De Laurentiis, 2008).  Endocrine therapies such as selective estrogen 
receptor modulators (e.g., Tamoxifen) and aromatase inhibitors (e.g., anastrazole, letrozole, and 
exemestane) are recommended for use in patients with ER positive breast cancer (NCCN, 2006).  
A meta-analysis of 12 randomized controlled trials showed that five years of tamoxifen therapy 
reduces the breast cancer mortality rate by 31% irrespective of age, progesterone receptor status, 
or other tumor characteristics (Early Breast Cancer Trialists’ Collaborative Group [EBCTCG]).  
Aromatase inhibitors (AIs) have been found to be more effective in reducing the disease-free 
survival rates as compared to tamoxifen (Coates et al., 2007), because of which they are 
considered as a first-line adjuvant therapy in postmenopausal women with ER-positive breast 
cancer.  AIs have also been found to be effective in reducing disease-free survival rates as 
compared to placebo in postmenopausal women who have completed five years of tamoxifen 
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therapy (Goss et al., 2003).  In spite of their proven effectiveness over tamoxifen, AIs are not 
usually recommended in premenopausal women since they have been found to be less effective 
in inhibiting ovarian estrogen production (Fabian, 2007).  Tissue-targeted therapies such as 
trastuzumab are recommended in women with HER2-positive breast cancer (NCCN, 2006).  
Lower risk of death and higher disease-free survival has been observed among HER2- positive 
breast cancer patients on trastuzumab and chemotherapy as compared to patients on 
chemotherapy only (Romond et al., 2005, Smith et al., 2007).  
 
Factors affecting guideline-consistent breast cancer treatment 
Treatment compliant with the established consensus guidelines for the treatment of breast cancer 
is important for optimal health outcomes in breast cancer patients (Herbert-Croteau et al., 2004, 
Maskarinec et al., 2011).  Various patient and healthcare-related characteristics have been found 
to be associated with receipt of guideline-consistent breast cancer treatment.  Several studies 
have found increasing age to be negatively associated with guideline-consistent breast cancer 
treatment (Ballard-Ballash et al., 1996, Haggstorm et al., 2005, Anderson et al., 2008, Chagpar et 
al., 2008, Rosato et al., 2009, Jagsi et al., 2010, Chien et al., 2012).  For example, in their study 
of elderly Medicare beneficiaries with breast cancer, Haggstorm et al. (2005) found that women 
aged 70-74 years were 18% less likely and women aged 75-79 years were 60% less likely to 
receive recommended regimen of radiation therapy after breast conserving surgery as compared 
to those aged 65-69 years.  The treatment of breast cancer has been found to vary with race.  
White women have been found to be more likely to receive guideline-consistent breast cancer 
treatment as compared to ethnic minorities such as African American women and Hispanic 
women (Haggstorm et al., 2005, Voti et al., 2006, Smith et al., 2010).  Prior studies have found a 
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positive association between possession of health insurance and receipt of guideline-consistent 
breast cancer treatment (Voti et al. 2006, Freedman et al., 2011).  Location of residence has been 
found to be an important predictor of guideline-consistent breast cancer treatment.  A study of 
elderly Medicare beneficiaries with breast cancer revealed that women living in rural areas were 
25% less likely to receive radiation therapy after breast conserving surgery as compared to 
women in metropolitan areas (Haggstorm et al., 2005).  Negative association between number of 
comorbidities and receipt of guideline-consistent breast cancer treatment has been observed in 
prior studies (Ballard-Barbash et al., 1996, Rosato et al., 2009, Jagsi et al., 2010).  Factors 
reflective of health services use, including use of mammography before breast cancer diagnosis 
and greater number of physician visits in the 12 months prior to diagnosis, have been reported to 
be positively associated with receipt of recommended regimen of radiation therapy after breast 
cancer surgery (Smith et al., 2010).   
Important hospital-level characteristics have been shown to affect receipt of guideline-
consistent breast cancer treatment.  Laliberte et al. (2005) reported that patients treated in 
hospitals with memberships in multiple National Cancer Institute (NCI)-funded research 
networks were 42% more likely to receive mastectomy and 60% more likely to receive breast 
conserving surgery with radiotherapy as opposed to breast conserving surgery only, as compared 
to hospitals without a membership in any NCI-funded research network.  In their study involving 
women with local stage breast cancer in Florida, Voti et al. (2006) found 21% greater odds of 
receiving guideline-consistent treatment among women treated in non-teaching hospitals as 
compared to those treated in teaching hospitals.  Hospital size has been found to positively 
impact receipt of guideline-consistent breast cancer treatment (Satariano et al., 1992, Grilli et al., 
1994, Guadagnoli et al., 1998).   For example, Guadagnoli et al. (1998) reported that breast 
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cancer patients treated in hospitals in Massachusetts with 100-249, 250-499, and 500 beds or 
more were 9.1, 6.5, and 7.9 times, respectively, more likely to receive radiotherapy after breast 
conserving surgery as compared to hospitals with less than 100 beds.   
Healthcare access-related variables such as number of primary care physicians and 
number of radiologists in the healthcare service area have been shown to be positively associated 
with receipt of guideline-consistent treatment of breast cancer (Ballard-Ballash et al., 1996).  
Studies have also found caseload of attending physicians to positively impact receipt of 
guideline-consistent breast cancer treatment (Satariano et al., 1992, Goy et al., 1998, Neuner et 
al., 2004, Ingram et al., 2005).  Surgeon specialty has been reported to be associated with receipt 
of radiation therapy after breast conserving surgery.  Chagpar et al. (2008) studied the factors 
associated with the breast cancer treatment received by patients enrolled in the North American 
Fareston vs. Tamoxifen Adjuvant (NAFTA) trial.  Surgical oncologists were found to be more 
likely to omit radiation therapy after breast conserving surgery as compared to general surgeons. 
 
Impact of pre-existing mental illnesses on receipt of guideline-consistent breast cancer treatment 
Pre-existing mental illness could be an important factor affecting breast cancer treatment.  Due to 
health-related issues such as poor eating and sleeping habits, lack of exercise, indulgence in 
smoking, alcohol, and drug abuse, and impaired immune system, individuals with mental 
illnesses are more likely to develop comorbid physical conditions, including breast cancer  
(Kendrick, 1996, Osborn, 2001, Mitchell et al., 2009, McGuinty et al., 2012).  These individuals 
also face challenges such as impaired communication skills, less motivation to undergo 
treatment, failure in follow-up care, and higher pain threshold due to which disparities in medical 
care are likely in these individuals (Lawrence and Kisely, 2010).  Limited research currently 
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exists regarding the association between pre-existing mental illnesses and receipt of guideline-
consistent breast cancer treatment.  A thorough literature review yielded only one study in this 
regard.  Goodwin et al. (2004) evaluated the effect of pre-existing depression on the treatment of 
breast cancer among elderly Medicare beneficiaries with breast cancer.  The authors found that 
women with pre-existing depression were 19% more likely to receive treatment non-consistent 
with established breast cancer treatment guidelines (simple mastectomy or breast-conserving 
surgery plus adjuvant irradiation for Stage 0, modified radical mastectomy or breast-conserving 
surgery with axillary dissection and adjuvant irradiation for Stage I or II, and chemotherapy for 
Stages III or IV) as compared to women without pre-existing depression.   
 
Breast Cancer Screening 
Screening for breast cancer offers potential for early detection of breast cancer at an 
asymptomatic stage (Paskett and McLaughlin, 2011).  Existing breast cancer screening 
modalities include mammography, clinical breast examinations (CBEs), breast self-examinations 
(BSEs), ultrasonography, and magnetic resonance imaging (MRI).  Mammography consists of 
imaging of breast tissue using ionizing radiations such as X-rays for the purpose of identification 
of in situ cancers or cancers that are too small to detect on physical examination.  Several 
randomized controlled trials have demonstrated that mammography screening is associated with 
mortality reduction in the range of 15-25% (Anderson et al., 1988, Chu et al., 1988, Tabar et al., 
1992, Tabar et al., 1995, Roberts et al., 1990. Bjurstam et al., 1997).  CBE is a physical 
examination of the breasts conducted by the healthcare provider for the purpose of detecting 
lumps or abnormalities.  While no trials have been conducted for determining the efficacy of 
CBEs as a sole screening procedure, they have been found to be useful as an addition to 
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mammography screening (Oestreicher et al., 2005).  Evidence regarding the effectiveness of 
BSEs as a screening procedure has been weak (Humphrey et al., 2002).  A randomized trial 
conducted by Thomas et al. (2002) showed no reduction in breast cancer-related mortality due to 
BSEs.  Ultrasonography is useful in detecting breast carcinomas underlying dense breast tissue.  
However, there is no evidence to support use of ultrasonography in population-based breast 
cancer screening programs (Teh et al., 1998, Ponhold et al., 2012).  MRIs have high sensitivity 
as compared to screening mammography, especially in high risk women (Lawrence et al., 1998).  
However, the effectiveness of MRIs in breast cancer screening is questionable due to high false 
positive rates (Paskett and McLaughlin, 2011).  
 
Breast cancer screening guidelines 
Mammography is the most effective and the most commonly used screening modality for the 
detection of breast cancer (Rim and Chellman-Jeffers, 2008, Vinitha Sree et al., 2011).  The 
current guidelines from ACS include yearly mammograms starting at age 40 until a woman is in 
good health (ACS).  The United States Preventive Services Task Force (USPSTF) recommends 
biennial mammography for women aged 50 to 74 years.  There has been a controversy associated 
with the USPSTF recommendations since there were no cancer specialists in the USPSTF panel, 
which issued the recommendations, and not all peer reviewed studies were considered while 
formulating the recommendations (Kopans, 2010, Woloshin and Schwartz, 2010, Hendrick et al., 
2011, Catalona et al., 2012).  Most of the other major medical organizations in the US such as 
the American College of Radiology (ACR), the American Medical Association (AMA), the 
Society of Breast Imaging (SBI), and the American Congress of Obstetricians and Gynecologists 
(ACOG) recommend annual mammography screening in women beginning at age 40 (Lee et al., 
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2010).  CBEs are recommended every 3 years for women in their 20s and 30s and every year for 
women aged 40 and over, and MRIs are recommended for women at high risk for breast cancer 
(women with a family history or a genetic tendency of breast cancer).  However, with proven 
effectiveness in multiple controlled trials, mammography is generally the mainstay of breast 
cancer screening for average risk women (Lee et al., 2010). 
 
Trends in mammography screening in the US 
The initial recommendation for mammography screening was issued in 1983 (ACS).  Since then, 
mammography has been widely adopted as a screening procedure in the US.  In general, the 
mammography screening rates have been found to be higher among women aged 50-64 years, 
college graduates, women with a high income, women having a usual source of care, women 
possessing a private HMO insurance, women who were born in the US, married women, 
employed women, women having a good or better health status, and women who have a family 
or personal history of breast cancer (Kim and Jang, 2008, Slomiany et al., 2008, Breen et al., 
2011).  In terms of trends in mammography screening rates over time, studies have found that the 
rates increased from the mid 1980s until 2000, after which a decline was observed until 2005 
(Breen et al., 2007, Chagpar et al., 2008, Zhou et al., 2010, Shi et al., 2011).  The decline was 
more evident in women with high family incomes, women with a private non-HMO insurance, 
women who were born in the US, non-Hispanic white women, women without personal or 
family history of breast cancer, employed women, women having at least a high school diploma, 
and those who reported being in poor or fair health (Chagpar et al., 2008, Ryerson et al., 2008, 
Slomiany et al., 2008, Zhou et al., 2010, Breen et al., 2011, Shi et al., 2011).  Possible reasons 
for the decline in mammography screening rates include decrease in the use of HRT in the early 
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2000s due to a Women’s Health Initiative  report suggesting an association between HRT and 
breast cancer, decrease in the number of mammography facilities between 2000 and 2003, 
increase in the number of women without a health insurance, increase in copayments for office 
visits, low reimbursements by insurers for mammography screenings, and increasing lawsuits 
against radiologists who read mammograms (Breen et al., 2007, Wolf et al., 2009).  Recent 
studies have reported that the mammography screening rates have not declined after 2005 (Breen 
et al., 2011).   
 
Factors associated with regular mammography screening 
Several factors have been found to be associated with routine receipt of mammography 
screening.  These factors can be broadly classified into socio-demographic factors, healthcare-
related factors, and psychological factors.  
 
Socio-demographic factors  
Socio-demographic factors such as race/ethnicity, age, education, income, and marital status 
have been found to be important predictors of routine receipt of mammography.  Several studies 
have reported that Caucasians are more likely to get regularly screened as compared to racial 
minorities such as African Americans, Asian Americans, and Hispanics (Song et al., 1998, Yood 
et al., 1999, Sabogral et al., 2001, Strzelczyk and Dignan, 2002).  Higher education has been 
found to be positively associated with routine receipt of mammography (Strzelczyk and Dignan, 
2002, Rahman et al., 2003, Raucher et al., 2005, Litaker et al., 2007).  For example, in their 
study of mammography screening behaviors of women residing in the Denver, Colorado, 
Rahman et al. (2003) found that high school graduates were 11% more likely and college 
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graduates were 33% more likely to receive routine mammography screenings as compared to 
women who did not graduate high school.  Prior studies have revealed that married women are 
more likely to get routinely screened as compared to single or divorced women (Yood et al., 
1999, Coughlin et al., 2004, Borrayo et al., 2009).  Residents in rural areas have been found to be 
less likely to get regularly screened as compared to residents in the urban areas.  A study of 
mammography screening behaviors of elderly women in California reported that residence in 
urban areas was associated with 5% lesser odds of irregular mammography screening as 
compared to residence in rural areas (Sabogral et al., 2001).  In terms of income, studies have 
found that individuals with higher income are more likely to undergo regular mammography 
than those with lower income (Phillips et al., 1998, Yood et al., 1999, Sabogral et al., 2001, 
Rakowski et al, 2006, Litaker et al., 2007).  However, individuals within the lowest income 
categories may not be least likely to receive routine mammography screening.  Rahman et al. 
(2006) studied the mammography screening behaviors of women aged 40 or more residing in 
Colorado from January 01, 1994 to December 31, 1998.  Women with income between $15,000 
and $24,999 had 16% lesser odds of receiving biennial mammograms as compared to those with 
incomes less than $15,000 (Rahman et al., 2003).  Similar results were observed by Rakowski et 
al. (2006).  In terms of association between age and mammography use, studies have found that 
women aged 40-49 years are less likely to routinely undergo mammography screening as 
compared to women aged 50-59 years.  Further, studies have found that the likelihood of receipt 
of routine mammography is lower in older age groups as compared to women in the age group 
50-59 years (Coughlin et al., 2004, Borrayo et al., 2009, Gierisch et al., 2010).  Non-indulgence 
in smoking and indulgence in alcohol use have been associated with regular mammography 
screening (Coughlin et al., 2004, Rosenberg et al., 2005, Rakowski et al., 2006, Borrayo et al., 
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2009).  Positive association between family history of breast cancer and regular use of 
mammography screening has been reported in several studies (Lerman et al., 1990, Strzelczyk 
and Dignan, 2002, Bobo et al., 2004, Rosenberg et al., 2005, Borraryo et al., 2009, Gierisch et 
al., 2010, Vyas et al., 2012).  A positive association between health status and regular 
mammography use has also been observed in previous studies (Bobo et al., 2004, Litaker et al., 
2007). 
 
 Healthcare-related factors 
Healthcare-related factors such as regular care from a healthcare provider, use of other 
preventive procedures, prior mammography or breast biopsy, and health insurance coverage play 
an important role in regular mammography screening.  Having a visit to a physician and 
obstetricians/gynecologists has been found to be a major factor influencing regular 
mammography screening (Taylor et al., 1995, Coughlin et al., 2004, Wu et al., 2007).  In 
addition, the frequency of visits has been found to positively affect mammography use.  In their 
study involving women enrolled in a New York HMO, Barr et al. (2001) found that women with 
three or more visits to a gynecologist had greater odds of receiving regular mammograms than 
those having one or two visits.  Prior studies have found a positive association between having a 
usual source of care and regular receipt of mammography (Bobo et al., 2004, Rakowski et al., 
2006, Litaker et al., 2007).  For example, in their analysis of the 2003 Health Information 
National Trends Survey, Rakowski et al. (2006) reported that women without a usual source of 
care were 69% less likely to receive repeat screening mammography within two years of the 
index mammogram as compared to women with a usual source of care.  Regular mammography 
screening has also been found to be positively impacted by regular use of other preventive tests 
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such as cervical cancer screening tests, colorectal cancer screening tests, influenza shots, 
cholesterol tests, blood glucose exams, and gynecologic exams (Phillips et al., 1998, Cummings 
et al., 2000, Raucher et al., 2005, Rosenberg et al., 2006, Wu et al., 2007).  A positive association 
has been observed between HRT use and adherence to mammography screening guidelines in 
previous studies (Bobo et al., 2004, Borrayo et al., 2009).  Previous receipt of mammography or 
diagnostic procedures such as breast biopsy has been found to be positively associated with 
regular receipt of mammography (Song et al., 1998, Bobo et al., 2004).  With most of the health 
insurances covering the cost of mammograms (CDC), it is not surprising that a positive 
association between possession of health insurance and routine mammography screening has 
been observed consistently in previous studies (Cummings et al., 2000, Strzelczyk and Dignan, 
2002, Coughlin et al., 2004, Litaker et al., 2007).  Previous studies have found factors related to 
healthcare access such as health maintenance organization (HMO) penetration rate, number of 
primary care physicians and obstetricians/gynecologists the area, and number of mammography 
screening facilities in the area to be positively associated with routine receipt of mammography 
screening (Phillips et al., 1998, Engelman et al. 2002, Baker et al., 2004, Benjamins et al., 2004, 
Litaker et al., 2007, Coughlin et al., 2008, Akinyemiju et al., 2012). 
 
Psychological factors 
Psychological factors such as perceived susceptibility towards breast cancer, perceived severity 
of breast cancer, and perceived benefits of mammography screening have been found to 
positively affect receipt of regular mammography screening (Lerman et al., 1990, Lee et al., 
1995, Taylor et al., 1995, Halabi et al., 2000, Rakowski et al., 2006).  Factors such as anxiety and 
embarrassment about screening and concern about cost have been found to negatively impact 
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regular mammography screening (Lerman et al., 1990, Maxwell et al., 1996).  Positive 
association has been observed between knowledge about breast cancer, mammography, and 
mammography screening guidelines and receipt of routine mammography (Glanz et al., 1992, 
Miller and Champion, 1996, Vyas et al., 2012).  Satisfaction with previous experience of 
mammography has also been found to positively impact regular mammography screening 
(Gierisch et al., 2009). 
 
Need for the study 
I. Need for determining the healthcare burden of breast cancer in the Medicaid population. 
Limited information currently exists about the healthcare burden of breast cancer in the Medicaid 
population.  Medicaid is one of the largest health insurance systems in the US providing 
coverage to over 60 million individuals.  Compared to other insured individuals, Medicaid 
enrollees have been found to have weaker socioeconomic and health-related characteristics.  An 
understanding of the estimates of the healthcare burden of breast cancer is important to the 
policy-makers for making decisions about resource allocation.  Only one study to date has 
determined the healthcare burden of breast cancer among Medicaid enrollees (Khanna et al., 
2011).  The study by Khanna et al. (2011) used data from West Virginia Medicaid fee-for-
service system to study breast cancer burden among women 21-64 years of age.  Though this 
study provided useful information regarding breast cancer burden among Medicaid enrollees, the 
fact that authors used single-state Medicaid data limited its generalizability.  
Chapter 2 determined the breast cancer-related healthcare utilization among women with 
breast cancer in the national Medicaid population using multistate Medicaid medical and 
pharmacy administrative claims data.  In addition, the incremental economic burden of breast 
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cancer in the Medicaid population was determined by comparing the healthcare use and costs of 
female recipients with breast cancer to those without breast cancer.  
 
II. Need for determining the impact of pre-existing mental illnesses on the receipt of 
guideline-consistent breast cancer treatment and breast cancer-related healthcare 
utilization among Medicaid enrollees diagnosed with breast cancer. 
It has been reported that up to 55% of the women with breast cancer do not receive 
recommended breast cancer treatments (Bloom et al., 2004, Landercasper et al., 2006, Foley et 
al., 2007, Worthington et al., 2008, Iyengar et al., 2010, Shirvani et al., 2011).  An understanding 
of the factors affecting the receipt of high quality breast cancer treatment, consistent with the 
established standards of breast cancer care, is necessary for planning steps towards improving the 
treatment of breast cancer patients.  While various individual and healthcare-related 
characteristics have been found to impact the receipt of guideline-consistent breast cancer 
treatment, scant literature currently exists about the association between pre-existing mental 
illnesses and receipt of guideline-consistent breast cancer treatment.  The only study in this 
regard was conducted by Goodwin et al. (2004), who determined the association between pre-
existing depression and receipt of guideline-consistent breast cancer treatment among elderly 
Medicare beneficiaries. While the work conducted by Goodwin et al. (2004) makes a significant 
contribution, only the impact of depression and not other mental illnesses was evaluated in the 
study.  Moreover, the findings of this study may not be generalizable to younger patients with 
breast cancer.  Pre-existing mental illnesses could also impact other important treatment-related 
outcomes, including healthcare utilization and costs, in breast cancer patients.  However, no 
information is available in this area in the previous literature.  
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Chapter 3 in the current study addressed this gap in the literature by determining the 
impact of pre-existing mental illnesses on the receipt of receipt of guideline-consistent breast 
cancer treatment and breast cancer-related healthcare utilization among Medicaid enrollees 
diagnosed with breast cancer.     
 
III. Need for determining the factors associated with use of repeat mammography screening 
among women enrolled in Medicaid. 
Regular mammography screening has been found to be more effective in reducing morbidity and 
mortality associated with breast cancer as compared to irregular or no mammography screening 
(Freedman et al., 2003, Moss et al., 2006, Hellquist et al., 2010).  However, less than half of the 
eligible women undergo regular mammography screening (Gierisch et al., 2009).  An 
understanding of factors affecting regular breast cancer screening is necessary for the purpose of 
devising healthcare interventions aimed at increasing the routine mammography screening rates.  
Limited information is available regarding factors affecting routine mammography screening in 
the Medicaid population.  In the past, Weir et al. (2011) and Bhanegaonkar et al. (2012) have 
determined the factors affecting routine mammography use among Medicaid enrollees belonging 
to certain states.  However, a major limitation of these studies was the limited generalizability of 
their findings.  
 Chapter 4 in this study determined the factors affecting the use of repeat mammography 
screening in a multistate Medicaid population.  Association between individual and 
neighborhood factors and repeat mammography screening was studied.   
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CHAPTER 2 
HEALTHCARE BURDEN ASSOCIATED WITH BREAST CANCER IN THE 
MEDICAID PROGRAM 
Introduction 
Breast cancer is the second most frequently diagnosed cancer and the second leading cause of 
cancer-related death in women (American Cancer Society [ACS]).  In 2013, an estimated 
296,980 women were expected to be diagnosed with breast cancer and 39,620 women were 
estimated to die from breast cancer in the United States (US) (ACS).  According to NIH 
estimates, one in eight women in the US will develop breast cancer in their lifetime (ACS).  The 
common risk factors for breast cancer are early age at menarche, late age at menopause and first 
child birth, family history of breast cancer, benign breast disease, use of hormone replacement 
therapy, nulliparity, physical inactivity, poverty, inadequate education, alcohol intake, and lack 
of health insurance (Gail et al., 1989, Lambe et al., 1996, Burke et al., 1997, Collaborative Group 
on Hormonal Factors in Breast Cancer, 1997, Smith-Warner et al., 1998, Grenall and Wood, 
2000, Chlebowski et al., 2003, Buchholz, 2009).   
Breast cancer is primarily treated by surgical removal of the tumor.  Surgical options for 
breast cancer include breast conserving surgery, radical mastectomy, modified radical 
mastectomy, and total mastectomy.  Radiation therapy is generally used post surgery to reduce 
the likelihood of recurrence of breast cancer.  Adjuvant systemic therapies such as 
chemotherapy, hormonal therapy, and tissue-targeted therapy have been associated with reduced
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recurrence rates and improved breast cancer-specific survival and are an important part of the 
breast cancer treatment regimen (Maughan et al., 2010). The prevalence of breast cancer in the 
US has increased over the past few decades on account of increasing breast cancer survival rates  
due to improved treatment regimens and early detection of breast cancer owing to increased 
mammography screening rates (Alacacioglu et al., 2009, Breast cancer facts and figures 2011-
2012).  There were nearly 3 million breast cancer survivors in the US in 2012, and this number is 
expected to increase to 3.8 million by 2022 (Siegel et al., 2012). 
 An understanding of healthcare utilization and costs associated with breast cancer is 
crucial for effective breast cancer management.  Information about the healthcare economic 
impact of breast cancer can help policy-makers in proper allocation of resources, thereby 
facilitating adequate treatment of the breast cancer patients.  Such information can also make 
policy-makers aware about the burden of breast cancer and, in turn, potentially trigger healthcare 
interventions aimed at reducing the morbidity and mortality associated with breast cancer.  
Several studies in the past have estimated the monetary impact of breast cancer among various 
patient populations (Fireman et al., 1997, Brown et al., 2001, Sasser et al., 2005, Barron et al., 
2008, Max et al., 2009, Khanna et al., 2011, Fu et al., 2012).  Barron et al. (2008) estimated the 
economic burden of breast cancer in a managed care population in the US.  The authors reported 
per member per month costs of breast cancer-related healthcare in the year 2004 to be $2,896 
among beneficiaries with breast cancer, with hospitalization costs accounting to nearly 50% of 
the total costs.  Surgery (62.3%) and pharmacotherapy (chemotherapy and hormonal therapy) 
(66.6%) were the most commonly received treatments.  The average annual direct medical costs 
attributable to breast cancer were found to be $27,588.  Similar to Barron et al. (2008), other 
studies have found significant healthcare costs associated with breast cancer (Fireman et al., 
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1997, Brown et al., 2001, Sasser et al., 2005, Max et al., 2009, Khanna et al., 2011, Fu et al., 
2012).  However, to date, only one study has examined the healthcare burden of breast cancer in 
the Medicaid population (Khanna et al., 2011).   
The Medicaid program is one of the largest health insurance programs in the US, 
providing coverage to nearly 60 million low-income and disabled individuals in the US (Kaiser 
Family Foundation [KFF]).  Compared to other insured individuals, Medicaid beneficiaries are 
more likely to suffer from chronic diseases and have less favorable overall health (Cunningham 
et al., 2005, Holohan et al., 2003).  On account of challenges such as inadequate social support, 
lower access to quality healthcare, illiteracy, poor nutrition, and problems with transportation 
and communication, the Medicaid population is inherently vulnerable to worse health outcomes 
(Landon and Epstein, 1999, Piecoro et al., 2001, Rowland, 2005).  The prevalence of breast 
cancer has been found to be higher in the Medicaid population as compared to the general 
population (Mullins et al., 2004).  It has also been reported that Medicaid recipients are more 
likely to have a higher breast cancer stage at diagnosis (Bradley et al., 2002).   
Limited information currently exists regarding the healthcare burden associated with 
breast cancer in the Medicaid population.  In one such study, Khanna et al. (2011) determined 
the healthcare burden of breast cancer in the West Virginia fee-for-service (FFS) Medicaid 
program using the 2005 data.  The authors reported average annual costs of breast cancer-related 
healthcare per recipient to be $5,637 among beneficiaries with breast cancer.  Hormone therapy 
(55.1%) was the most commonly received treatment.  The average annual incremental costs 
associated with breast cancer were reported to be $3,408 per recipient.  While the work 
conducted by Khanna et al. (2011) provides useful information about the healthcare burden of 
breast cancer in the Medicaid population, updated information in this regard, that is more 
35 
 
generalizable, is needed.  In their study, Khanna et al. (2012) analyzed single-state Medicaid 
data.  Further, the authors used only Medicaid FFS data and did not consider Medicaid managed 
care data in their study.  Over the years, an increasing number of Medicaid enrollees has been 
shifted to Medicaid managed care.  As of February 2010, over 70 percent of the Medicaid 
enrollees were receiving their healthcare services through managed care and this number is 
expected to increase further in the coming years (KFF).  In order to obtain an exhaustive estimate 
of the healthcare burden of breast cancer in the Medicaid population, it is necessary to take into 
account the breast cancer-related healthcare utilization and costs in Medicaid managed care 
enrollees.  
The objective of the current study was to determine the healthcare burden associated with 
breast cancer in the Medicaid population using multistate Medicaid medical and pharmacy 
administrative claims data.  Breast cancer-related medical services and treatment (surgery, 
radiation, hormonal therapy, and chemotherapy) utilization among Medicaid enrollees with 
breast cancer was determined.  In addition, the incremental healthcare use and costs associated 
with breast cancer were determined by comparing the all-cause healthcare use and costs of 
women with and without breast cancer.  
 
Methods 
Data source 
The 2006-2008 Medicaid analytic extract (MAX) files for 39 states (all states except Alaska, 
Hawaii, Maine, Missouri, Montana, North Dakota, Pennsylvania, South Dakota, Utah, 
Wisconsin, Wyoming, and District of Columbia) were used for the purpose of the study.  
Medicaid Analytic Extract (MAX) files are a set of person-level files which are made available 
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by Centers for Medicare and Medicaid services (CMS) for the purpose of supporting research 
and policy analysis.  Information about Medicaid enrollment, utilization, and expenditure is 
made available through MAX personal summary, inpatient services, other therapy, and 
prescription drug files.  The MAX personal summary file contains demographic data such as date 
of birth, gender, race, and age, basis of eligibility, monthly enrollment status, period of managed 
care eligibility, and utilization summary.  The MAX inpatient file contains details about inpatient 
services utilized by the Medicaid enrollees with important fields such as International 
Classification of Diseases, ninth revision, clinical modification (ICD-9-CM) diagnoses codes (up 
to ten diagnostic fields), ICD-9-CM, Current procedural terminology 4
th
 edition (CPT-4) or 
Healthcare Common Procedure Coding System (HCPCS) procedure codes (up to seven 
procedure fields), service beginning date, ending date of service, and payment amount.  The 
MAX prescription drug file contains information about the prescriptions dispensed to recipients, 
including days of supply, quantity supplied, National Drug Classification (NDC) code, 
prescription date, and the amount paid.  The MAX other therapy file contains information about 
all non-institutional Medicaid services provided to Medicaid enrollees, including physician 
services, lab/X-ray, and clinic services.  Important fields in this file include ICD-9-CM diagnoses 
codes (up to two diagnostic fields), ICD-9-CM, CPT-4, or HCPCS procedure codes (one 
procedure field), provider identification number, service beginning date, ending date of service, 
place of service, charge amount, payment amount, and UB-92 revenue codes.  In order to protect 
patient privacy, each of the files was made available to the researcher without identifying the 
individual recipients.  All the files were linked using a unique encrypted recipient identification 
number. Approval for the conduct of the project was taken from Institutional review board (IRB) 
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at University of Mississippi, following which data use agreement (DUA) was executed with 
CMS through Research Data Assistance Center (ResDAC).   
 
Study sample 
The target population for this study consisted of women who were continuously enrolled in the 
Medicaid program during the years 2006-2008 and who were at least 18 years of age as of 
January 01, 2006 and less than 65 years of age as of December 31, 2008.  Since the occurrence 
of breast cancer in males and adolescents is rare, the study included only women aged 18 years 
or more.  In addition, the study excluded women aged 65 years or more since Medicare is the 
primary payer in these individuals, and the MAX files do not have complete information about 
their healthcare use.  Women aged less than 65 years, who were enrolled in both Medicare and 
Medicaid, were also excluded from the study due to incomplete data in the MAX files.  Women 
with at least one medical claim with a primary diagnosis of breast cancer (ICD-9-CM codes of 
174 [Malignant neoplasm of the female breast], 233.0 [Carcinoma in situ of breast], 238.3 
[Neoplasm of uncertain behavior of breast], and 239.3 [Neoplasm of unspecified nature of 
breast]) during the years 2007 or 2008 were classified as breast cancer cases (Barron et al., 
2008).  For the purpose of determining incremental healthcare use and costs associated with 
breast cancer, one control without a diagnosis of breast cancer during the study period was 
selected from the target population for each case by matching on age (± 5 years), race, state of 
residence, location of residence (metropolitan, suburban, or rural), and the type of reimbursement 
system (FFS only [recipients who were enrolled in FFS Medicaid during 2006-2008] and 
managed care [recipients who were enrolled in Medicaid managed care for at least one month 
during 2006-2008]).  Cases without any corresponding control were excluded from the study. 
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Measures 
Treatment use among breast cancer patients was reported as number and percentage of patients 
per year having at least one claim for surgery, radiotherapy, chemotherapy, hormonal therapy, 
and other drugs during the years 2007 and 2008.  Breast cancer surgery was identified from the 
MAX inpatient and other therapy file records with CPT-4 codes of 19120-19126, 19160-19162, 
19180, 19182, 19200, 19220, 19240, 19260, 19271, 19272, 19290-19298, 19316-19396, and 
19499 and ICD-9-CM procedure codes of 8520-8525, 8534-8536, 8541-8548, and 8663.  
Radiation therapy was determined from the records within the MAX inpatient and other therapy 
file with CPT-4 codes of 77261-77418, 77427-77499, and 77520-77525, ICD-9-CM procedure 
codes of 9221-9226, and ICD-9-CM diagnosis codes of V580, V661, and V671.  Chemotherapy 
was identified from the MAX inpatient and other therapy file records with HCPCS codes of 
J8520 and J8521 (capecitabine), J8530 (oral cyclophosphamide), J9070-J9097 
(cyclophosphamide), J9190 (5-flurouracil), J9260 and J9250 (methotrexate), J9201 
(gemcitabine), J9390 (vinorebine), J9265 (paclitaxel), J9170 (docetaxel), J9000 and J9001 
(doxorubicin), J9178 (epirubicin), J9045 (carboplatin), J9060 and J9062 (cisplatin), and J9355 
(trastuzumab), ICD-9-CM procedure code of 9225, and ICD-9-CM diagnosis codes of V581, 
V662, and V672.  In addition, records within the MAX drug file with NDC codes for the 
chemotherapy drugs were used to identify chemotherapy use.  Hormone therapy was identified 
using the MAX inpatient and other therapy file records with HCPCS codes of S0187 
(tamoxifen), J9395 (fulvestrant), S0170 (anastrozole), and S0156 (exemestane) and from the 
MAX prescription drug file records with NDC codes for the drugs.  Drugs goserelin (HCPCS 
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code of J9202) and megestrol (HCPCS code of S0179) were classified as other drugs since they 
do not belong to a particular category (Barron et al., 2008). 
Breast cancer-related healthcare use among cases of breast cancer was determined in the 
form of number of breast cancer-related inpatient, outpatient, and emergency room (ER) visits.  
An inpatient visit was considered to be breast cancer-related if the primary diagnosis code 
associated with the record was for breast cancer (ICD-9-CM code of 174, 233.0, 238.3, or 
239.3).  Outpatient and ER visits were considered to be breast cancer-related if the primary 
and/or secondary diagnosis code associated with the records were for breast cancer.  The 2007 
and 2008 MAX inpatient and other therapy files were used for identifying breast cancer-related 
healthcare use.  The MAX inpatient file is an event-level file and hence each observation was 
considered as one visit.  Observations with place of service codes of 11 (office), 22 (outpatient 
hospital), 24 (ambulatory service center), 50 (federally qualified health center), 71 (state or local 
public health clinic), or 72 (rural health clinic) and type of service codes of 08 (physicians), 10 
(other practitioners), 11 (outpatient hospital), 12 (clinic), 37 (nurse practitioner services) or those 
with procedure codes 99201-99215, 99241-99245, 99354-99355, 99381-99429 in the other 
therapy file were classified as outpatient visits.  The MAX other therapy file is a claim-level file 
and hence we defined outpatient visits based on the date of service.  If a recipient had one or 
more observations on a particular day that conformed to the above mentioned criteria, she was 
considered to have had an outpatient visit on that day.  Observations with place of service code 
of 23 in the other therapy file and those with revenue code of 450-459 or procedure codes of 
99281-99285 in the other therapy file or inpatient file were considered as ER visits.  Mean 
number of breast cancer-related inpatient, outpatient, and ER visits per recipient per year were 
reported.   
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All results for breast cancer-related healthcare utilization were reported by age, race, and 
location of residence.  Age was classified into five categories: 18-29 years, 30-39 years, 40-49 
years, 50-59 years, and 60-64 years.  Race was be categorized as white, black, Hispanic or 
Latino, Asian, Native Hawaiian or other Pacific islander, American Indian or Alaskan Native, 
and others (consisting of more than one race and unknown race).  State of residence was 
classified into 39 categories.  The location of residence consisted of categories of metropolitan, 
suburban, rural, and unknown and was defined for each recipient based on the United States 
Department of Agriculture (USDA) rural-urban continuum codes: metropolitan location (codes 
0-3), suburban location (codes 4-5), and rural location (codes 6-9).  The rural-urban continuum 
codes were determined based on the Federal Information Processing Standard (FIPS) code for 
the county of residence listed in the 2006 MAX personal summary file.  The location of 
residence for recipients with a missing value for the FIPS code was classified as unknown. 
 Incremental economic burden associated with breast cancer in the Medicaid population 
was measured based on all-cause healthcare costs among Medicaid recipients with and without 
breast cancer.  The data from the 2007 and 2008 MAX personal summary files were used for this 
purpose.  Costs were considered from the perspective of Medicaid and hence only the amount 
reimbursed by Medicaid was used while determining the costs.  Other payments such as 
copayments, deductibles, and third party payer amounts were not included in the cost calculation.  
While assessing healthcare costs, Charlson comorbidity index (CCI) was included as a measure 
of case mix differences between Medicaid enrollees with and without breast cancer.  The 
D’Hoore adaptation of CCI was used in this study.  CCI was calculated based on the medical 
records for the recipients during the year 2006.  Breast cancer was excluded from the CCI 
calculation. 
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Statistical analysis 
The mean number of breast cancer-related inpatient, outpatient, and ER visits per recipient per 
year was compared among different categories of age, race, and location of residence using 
Kruskal-Wallis one-way analysis of variance test (ANOVA).  Post hoc comparisons were 
performed using a macro developed by Elliott and Hynan (2011).  The mean number of all-cause 
inpatient, outpatient, and ER visits and the total all-cause healthcare costs per year were 
compared between Medicaid enrollees with and without breast cancer using the non-parametric 
Wilcoxon rank sum test.  Multivariable comparison of all-cause costs between recipients with 
and without breast cancer was performed using a generalized linear model (GLM) with log link 
and Poisson distribution.  The suitable distribution for the GLM was determined using Modified 
Park’s test.  CCI was used as the covariate in the GLM.  Level of significance (α) of 0.05 was 
used in all the analyses.  Means and standard deviations were reported for the continuous 
variables.  Frequencies and percentages were reported for the categorical variables.  The greedy 
algorithm was used for matching cases and controls.  All analyses were performed using 
Statistical Analysis System (SAS) version 9.3 (SAS Institute Inc., Cary, NC).  The SAS 
procedure PROC GENMOD was used for fitting the GLM.  
 
Results 
A total of 34,675 recipients with one or more medical claims with a primary diagnosis of breast 
cancer was identified during 2007-2008.  Among these, 477 recipients did not have a 
corresponding matched control and hence were excluded from the study.  Table 2.1 presents the 
demographic characteristics of the final study sample.  Among the 34,198 cases included in the 
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study sample, nearly 32% belonged to the age group 40-49 years, whereas nearly 44% were aged 
50-59 years.  In terms of race, roughly 43% were whites, 22% were blacks, and the remaining 
35% consisted of ethnic minorities such as Hispanics or Latinos, Asians, Native Hawaiians/ 
other Pacific islanders, and American Indians/ Alaskan natives.  Majority of the study sample 
(82.26%) resided in metropolitan counties.  
 
Table 2.1. Demographic characteristics of Medicaid enrollees with breast cancer 
Characteristic N (%) 
Age (years)  
18-29 1,202(3.52) 
30-39 3,464 (10.13) 
40-49 10,862 (31.76) 
50-59 15,114 (44.20) 
60-64 3,556 (10.40) 
Race  
White 14,658 (42.86) 
Black 7,505 (21.95) 
Hispanic or Latino 4,247 (12.42) 
Asian 1,763 (5.16) 
Native Hawaiian or other 
Pacific islander 
593 (1.73) 
American Indian or 
Alaskan native 
307 (0.9) 
Others 5,125 (14.99) 
Location  
Metropolitan 28,132 (82.26) 
Suburban 2,070 (6.05) 
Rural 3,559 (10.41) 
Unknown 437 (1.28) 
Total 34,198 (100) 
 
Table 2.2 presents the use of different types of breast cancer treatments among recipients 
with breast cancer in the years 2007 and 2008.  Roughly 42% and 46% of the recipients had one 
or more claims for any breast cancer treatment in 2007 and 2008, respectively.  Hormonal 
therapy was the most commonly used treatment (26.75% and 28.13% of the recipients in 2007 
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and 2008 respectively).  Breast cancer surgery was the next most commonly used treatment 
(12.49% and 13.60% of the recipients in 2007 and 2008 respectively), followed by chemotherapy 
(8.25% and 9.70% of the recipients in 2007 and 2008 respectively) and radiation therapy (7.62% 
and 9.04% of the recipients in 2007 and 2008 respectively). 
 
Table 2.2. Annual treatment utilization among Medicaid enrollees with breast cancer, 
2007-2008. 
 2007 2008 
Treatment N (%)
a
 N (%)
a
 
Breast cancer surgery 4,273 (12.49)  4,652 (13.60) 
Radiation therapy 2,643 (7.62) 3,092 (9.04) 
Chemotherapy 2,822 (8.25) 3,316 (9.70) 
Hormonal therapy 9,149 (26.75) 9,620 (28.13) 
Other therapy 445 (1.30) 604 (1.77) 
a
Percentage is based on total number of recipients with breast cancer (34,198) 
 
 Table 2.3 describes the average annual breast cancer-related healthcare use among 
recipients with breast cancer during 2007-2008.  With an average of 4.345 (±7.312) visits per 
recipient per year, outpatient visits accounted for over 95% of the breast cancer-related 
healthcare visits.  Breast cancer-related outpatient visits were found to vary by age and race.  In 
the post-hoc tests, it was found that recipients aged 18-29 years (2.472 visits per recipient per 
year) had lower use of breast cancer-related outpatient services as compared to those aged 30-39 
(4.329 visits per recipient per year), 40-49 (4.606 visits per recipient per year), 50-59 (4.380 
visits per recipient per year), and 60-64 years (4.074 visits per recipient per year) (Tables 2.3 and 
2.3a).  Breast cancer-related outpatient use was higher in Hispanics/ Latinos (4.824 visits per 
recipient per year) as compared to whites (4.164 visits per recipient per year) and in American 
Indians/Alaskan natives (5.952 visits per recipient per year) as compared to whites and blacks 
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(4.477 visits per recipient per year) (Tables 2.3 and 2.3b).  The average breast cancer-related 
inpatient visits per patient per year were found to be 0.039 (±0.183).  Breast cancer-related 
inpatient visits were found to vary across different categories of age and race.  Breast cancer-
related inpatient use was higher in recipients aged 30-39 years (0.052 visits per recipient per 
year) as compared to those aged 18-29 years (0.030 visits per recipient per year) and 50-59 and 
60-64 years (0.036 visits per recipient per year) (Tables 2.3 and 2.3c).  American 
Indians/Alaskan natives had the highest number of breast cancer-related inpatient visits per 
recipient per year (0.070) among all the races (Tables 2.3 and 2.3d).  The average breast cancer-
related ER visits per recipient per year were found to be 0.086 (±0.636).  The use of breast 
cancer-related ER services was higher in recipients aged 30-39 (0.104 visits per recipient per 
year) and 40-49 years (0.098 visits per recipient per year) as compared to those aged 18-29 years 
(0.052 visits per recipient per year), 50-59 years (0.073 visits per recipient per year), and 60-64 
years (0.091 visits per recipient per year) (Tables 2.3 and 2.3e).  American Indians/Alaskan 
natives had the highest number of breast cancer-related ER visits (0.345 visits per recipient per 
year) among all the races.  Blacks had higher use of breast cancer-related ER services (0.097 
visits per recipient per year) as compared to whites (0.085 visits per recipient per year) (Tables 
2.3 and 2.3f).  In terms of location, recipients with unknown location had lesser number of breast 
cancer-related ER visits (0.014 visits per recipient per year) as compared to those residing in 
metropolitan (0.088 visits per recipient per year), suburban (0.075 visits per recipient per year), 
and rural (0.075 visits per recipient per year) locations (Tables 2.3 and 2.3g).  
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Table 2.3. Average annual breast cancer-related healthcare utilization among Medicaid enrollees, 2007-2008  
Demographic 
characteristic 
Inpatient 
visits 
p Outpatient visits p 
Emergency 
room visits 
p 
Age (years)  < 0.0001  < 0.0001  < 0.0001 
18-29 0.030  2.472  0.052  
30-39 0.052  4.329  0.104  
40-49 0.044  4.606  0.098  
50-59 0.036  4.380  0.073  
60-64 0.036  4.074  0.091  
Race  < 0.0001  < 0.0001  < 0.0001 
White 0.031  4.164  0.085  
Black 0.049  4.477  0.097  
Hispanic or Latino 0.032  4.824  0.097  
Asian 0.051  3.995  0.062  
Native Hawaiian or 
other Pacific islander 
0.028 
 
4.642 
 
0.062 
 
American Indian or 
Alaskan native 
0.070 
 
5.952 
 
0.345 
 
Others 0.050  4.280  0.054  
Location  0.654  0.306  0.0003 
Metropolitan 0.042  4.367  0.088  
Suburban 0.031  4.309  0.075  
Rural 0.031  4.261  0.075  
Unknown 0.028  3.977  0.014  
Total 0.039  4.345  0.086  
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Table 2.3a. Results for the post hoc tests with outpatient visits as the dependent variable and age as the independent variable 
 18-29 30-39 40-49 50-59 60-64 
18-29 -     
30-39 sig -    
40-49 sig sig -   
50-59 sig sig ns -  
60-64 sig sig ns ns - 
sig: significant, ns: non-significant 
 
Table 2.3b. Results for the post hoc tests with outpatient visits as the dependent variable and race as the independent variable 
 
White Black 
Hispanic 
or Latino 
Asian 
Native Hawaiian 
or other Pacific 
islander 
American 
Indian or 
Alaskan native 
Others 
White -       
Black ns -      
Hispanic or Latino sig ns -     
Asian ns ns ns -    
Native Hawaiian or 
other Pacific 
islander 
ns ns ns ns -   
American Indian or 
Alaskan native 
sig sig ns ns ns -  
Others ns ns ns ns ns sig - 
sig: significant, ns: non-significant 
 
Table 2.3c. Results for the post hoc tests with inpatient visits as the dependent variable and age as the independent variable 
 18-29 30-39 40-49 50-59 60-64 
18-29 -     
4
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30-39 sig -    
40-49 ns ns -   
50-59 ns sig ns -  
60-64 ns sig ns ns - 
sig: significant, ns: non-significant  
 
Table 2.3d. Results for the post hoc tests with inpatient visits as the dependent variable and race as the independent variable 
 
White Black 
Hispanic 
or Latino 
Asian 
Native Hawaiian 
or other Pacific 
islander 
American 
Indian or 
Alaskan native 
Others 
White -       
Black ns -      
Hispanic or Latino ns ns -     
Asian ns ns ns -    
Native Hawaiian or 
other Pacific 
islander 
ns ns ns ns -   
American Indian or 
Alaskan native 
sig ns sig sig sig -  
Others ns ns ns ns ns sig - 
sig: significant, ns: non-significant 
 
Table 2.3e. Results for the post hoc tests with emergency room visits as the dependent variable and age as the independent 
variable 
 18-29 30-39 40-49 50-59 60-64 
18-29 -     
30-39 sig -    
40-49 sig ns -   
50-59 ns sig sig -  
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60-64 ns sig sig ns - 
sig: significant, ns: non-significant 
 
Table 2.3f. Results for the post hoc tests with emergency room visits as the dependent variable and race as the independent 
variable 
 
White Black 
Hispanic 
or 
Latino 
Asian 
Native Hawaiian 
or other Pacific 
islander 
American Indian 
or Alaskan 
native 
Others 
White -       
Black sig -      
Hispanic or Latino ns ns -     
Asian sig sig sig -    
Native Hawaiian or 
other Pacific 
islander 
ns sig ns ns -   
American Indian or 
Alaskan native 
sig sig sig sig sig -  
Others sig sig sig ns ns sig - 
sig: significant, ns: non-significant 
 
 
Table 2.3g. Results for the post hoc tests with emergency room visits as the dependent variable and location as the independent 
variable 
 Metropolitan Suburban Rural Unknown 
Metropolitan -    
Suburban ns -   
Rural ns ns -  
Unknown sig sig sig - 
sig: significant, ns: non-significant 
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 Table 2.4 depicts the average annual all-cause healthcare use and costs incurred during 
2007-2008 among recipients with breast cancer and the matched controlled group of enrollees 
without breast cancer.  Women with breast cancer had significantly higher number of inpatient 
(0.38±0.97 vs. 0.27±0.81, p < 0.0001), outpatient (17.21±14.90 vs. 11.14±14.09, p < 0.0001), 
and ER visits (1.35±3.03 vs. 1.22±3.00, p < 0.0001) per recipient per year as compared to 
women without breast cancer.  The total all-cause healthcare costs per recipient per year were 
also higher among women with breast cancer ($14,954.83±20,802.83) as compared to those 
without breast cancer ($11,330.89±17,613.13, p < 0.0001).  The results of the generalized linear 
model (GLM) fitted for multivariable comparison of all-cause healthcare costs between 
recipients with and without breast cancer are presented in Table 2.5.  Recipients with breast 
cancer had nearly 23.4% higher costs per recipient per year as compared to those without breast 
cancer (estimate = 0.2014, 95% confidence interval = 0.1955 – 0.2252, p < 0.0001).  Based on 
the results of the GLM, the predicted per recipient per year costs were found to be 
$15,894.94±11,073.78 in recipients with breast cancer and $11,007.56±4,996.16 in recipients 
without breast cancer.  
 
Table 2.4. Average annual all-cause healthcare utilization and costs among Medicaid 
enrollees with and without breast cancer, 2007-2008 
Variable Enrollees with breast 
cancer 
(N = 34,198) 
Enrollees without breast 
cancer 
(N = 34,198) 
p 
Inpatient visits per year, 
Mean(SD)  
0.38(0.97) 0.27(0.81) <0.0001 
Outpatient visits per year, 
Mean(SD) 
17.21(14.90) 11.14(14.09) <0.0001 
Emergency room visits per 
year, Mean(SD) 
1.35(3.03) 1.22(3.00) <0.0001 
Total costs per year ($), 
Mean(SD) 
14,954.83(20,802.83) 11,330.89(17,613.13) <0.0001 
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SD: standard deviation 
 
 
Table 2.5. Generalized linear model for comparison of all-cause healthcare costs between 
Medicaid enrollees with and without breast cancer, 2007-2008 
 Estimate 95% confidence interval p 
Intercept 9.0635 9.0520 ‒ 9.0751 < 0.0001 
Case 0.2104 0.1955 ‒ 0.2252 < 0.0001 
Control 0   
Charlson comorbidity 
index 
0.1827 0.1786 ‒ 0.1868 < 0.0001 
 
 
Discussion 
This study determined the healthcare burden of breast cancer in the economically 
underprivileged Medicaid population using recent multistate Medicaid data.  To the best of our 
knowledge, the current study is the first to provide estimates of breast cancer burden in the 
national Medicaid population.  Proportions of breast cancer patients receiving different breast 
cancer treatments (surgery, radiation therapy, chemotherapy, hormonal therapy, and other 
therapies) were reported.  Breast cancer-related healthcare use in the form of inpatient, 
outpatient, and ER visits was determined in recipients with breast cancer.  The incremental 
healthcare burden attributable to breast cancer was determined by comparing the all-cause 
healthcare use and costs between Medicaid recipients with breast cancer and a matched control 
group of recipients without breast cancer.   
Hormonal therapy was the most commonly used treatment in 2007 (~27% of the 
recipients receiving treatment) and 2008 (~28% of the recipients receiving treatment) among 
recipients with breast cancer.  Adjuvant therapies including hormonal therapy, chemotherapy, 
and radiation therapy accounted for ~75% of the treatment use whereas surgical treatments were 
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responsible for ~22% of the treatment use in 2007 and 2008.  As mentioned previously, breast 
cancer treatment generally consists of surgical removal of the tumor followed by adjuvant 
therapies to prevent breast cancer recurrence.  Thus the results obtained in this study indicate that 
considerable proportion of the women in our study sample included women who were diagnosed 
with breast cancer and received their primary surgical treatment during years prior to the study 
period.  
 Outpatient visits accounted for more than 95% of the breast cancer-related healthcare 
visits among recipients with breast cancer.  This finding could be attributed to the fact that most 
of the breast cancer treatments including surgical treatments and adjuvant therapies are 
administered in outpatient settings in the recent times due to technological advances in breast 
cancer treatment.  Inpatient facilities are used in only a few patients undergoing mastectomies 
and axillary lymph node dissections (Russo et al., 2006).  Regarding the breast cancer-related 
healthcare use in different age groups, greatest per recipient per year breast cancer-related 
outpatient visits were observed in the age group 40-49 years whereas lowest per recipient per 
year breast cancer-related outpatient visits were observed in the age group 18-29 years.  The age 
group 30-39 years was found to have highest per recipient breast cancer-related inpatient and ER 
visits, whereas the age group 50-59 years had lowest per recipient per year breast cancer-related 
inpatient and ER visits.  Ethnic minorities were found to have greater number of per recipient per 
year breast cancer-related inpatient, outpatient, and ER visits as compared to whites for the most 
part.  These results provide a cross-sectional snapshot of the breast cancer-related healthcare use 
in different demographic categories during 2007-2008, which could be useful from the point of 
view of resource allocation for the Medicaid policy makers.  However, direct comparison of the 
healthcare use across these demographic categories was not possible due to lack of information 
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about time since diagnosis of breast cancer and stage of breast cancer in the MAX files.  It is 
possible that recipients belonging to demographic categories with higher breast cancer-related 
healthcare use were more recently diagnosed with breast cancer or had higher stage of breast 
cancer as compared to those belonging to categories with lower healthcare use.  Details about 
clinical characteristics of the cancer and date of diagnosis are available in cancer registries.  
Future studies could use cancer registry-linked administrative claims data to study the impact of 
various demographic and clinical factors on breast cancer-related healthcare use in the Medicaid 
population.  
Recipients with breast cancer were found to have significantly higher average annual all-
cause inpatient, outpatient, and ER visits as compared to those without breast cancer.  These 
results are indicative of the considerable healthcare utilization associated with breast cancer in 
the Medicaid population.  Our findings are somewhat consistent to those of Khanna et al. (2011), 
who also reported incremental healthcare use associated with breast cancer in the West Virginia 
Medicaid FFS population.  In that study, women with breast cancer had significantly greater 
average all-cause physician office visits as compared to those without breast cancer.     
In addition to average annual healthcare visits, recipients with breast cancer were also 
found to have higher average annual all-cause costs ($14,954.83) as compared to those without 
breast cancer ($11,330.89).  In the multivariable analyses that controlled for CCI, recipients with 
breast cancer were found to have ~23.4% higher per recipient per year costs as compared to 
those without breast cancer.  The predicted per recipient per year costs in the adjusted model 
were found to be $15,894.94(±11,073.78) in recipients with breast cancer and 
$11,007.56(±4,996.16) in recipients without breast cancer, resulting in an incremental difference 
of $4,887.38.  Our finding of $14,955 average per recipient per year all-cause costs among 
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recipients with breast cancer is similar to that of Khanna et al. (2011), who found average costs 
of $16,435 among FFS Medicaid recipients in West Virginia.  The slightly lower cost estimates 
in our study could be because we included recipients enrolled in both Medicaid managed care 
and FFS, whereas the Khanna et al. (2012) study only included FFS recipients.  One of the major 
reasons for the increasing movement towards Medicaid managed care is the cost savings 
associated with the managed care environment as compared to traditional FFS system.   
Some limitations in the study need to be addressed.  Coding errors might have occurred 
during claims processing which might have impacted the study results.  Individuals eligible for 
both Medicare and Medicaid (dual eligibles) were excluded from the study on account of 
incomplete data and hence the results obtained from the study may not be representative of the 
entire Medicaid population.  The encounter data for the managed care enrollees submitted by the 
states do not undergo quality checks and hence can contribute to the inaccuracy in the results.  
Healthcare utilization and costs generally vary by the stage of cancer and treatment phrase.  
However these factors were not taken into account in the current study due to lack of information 
in the MAX files.  The current study did not consider the possible relocation of recipients 
between states and counties during the study period.  The study results must be interpreted in 
light of these limitations.  
This study provided important insights concerning the healthcare utilization and costs 
associated with breast cancer in the Medicaid population.  Outpatient visits accounted for the 
majority of the breast cancer-related healthcare utilization among recipients with breast cancer.  
Breast cancer-related healthcare utilization was higher among middle-aged women and ethnic 
minorities as compared to adolescent and elderly women and whites respectively.  Considerable 
healthcare burden of breast cancer was observed in the Medicaid population with average annual 
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all-cause healthcare utilization and costs being significantly higher among recipients with breast 
cancer as compared to a matched control group of recipients without breast cancer.  Policy 
makers could use the findings from this study for efficient resource allocation and planning 
strategies aimed at reducing disparities in the treatment of breast cancer patients enrolled in 
Medicaid. 
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CHAPTER 3 
IMPACT OF PRE-EXISTING MENTAL ILLNESSES ON RECEIPT OF GUIDELINE-
CONSISTENT BREAST CANCER TREATMENT AND HEALTHCARE UTILIZATION 
AMONG WOMEN DIAGNOSED WITH BREAST CANCER 
Introduction 
Breast cancer is the most common cancer among women, after skin cancer.  Breast cancer is also 
the second leading cause of cancer-related mortality in women, exceeded only by lung cancer 
(American Cancer Society [ACS]).  In the year 2013, roughly 300,000 incident cases of breast 
cancer were expected to occur and 39,620 women were estimated to die from breast cancer in the 
United States (US) (ACS).  It has been estimated that nearly 12% of the women in the US will 
develop breast cancer in their lifetime (ACS).  Despite being associated with considerable 
morbidity and mortality, breast cancer is one of the most treatable cancers if detected early.  The 
primary treatment of breast cancer consists of surgical removal of the tumor.  Some of the 
aggressive types of breast cancer surgeries include radical mastectomy, modified radical 
mastectomy, and total mastectomy.  These procedures involve removal of the whole breast that 
has cancer.  A relatively less aggressive surgical breast cancer treatment regimen is breast-
conserving surgery, a procedure performed to remove the cancer but not the breast itself.  
Adjuvant treatments such as radiotherapy, hormonal therapy, chemotherapy, and tissue-targeted 
therapies have been found to reduce the likelihood of breast cancer recurrence and are an integral 
part of the breast cancer treatment regimen (Maughan et al., 2010).  
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 Major medical organizations, including the American Society of Clinical Oncology 
(ASCO), the National Comprehensive Cancer Network (NCCN), and the National Institute of 
Health (NIH), have issued guidelines for the treatment of breast cancer in order to inform  
physicians about the state-of-the-art breast cancer treatments and facilitate standard management 
of breast cancer patients (Iyengar et al., 2010).  These guidelines are based on the breast cancer 
clinical research conducted over the past few decades (Ragaz et al., 1997, Overgaard et al., 1997, 
Fisher et al., 2002, Goss et al., 2003, Romond et al., 2005, Fisher et al., 2006, Coates et al., 2007, 
Smith et al., 2007).  Some of the main guidelines issued by these organizations include the use of 
radiotherapy after breast conserving surgery in patients with stage I and stage II breast cancers 
(NIH consensus guidelines for the treatment of breast cancer, 1990, Recht et al., 2001, NCCN, 
2006, Maughan et al., 2010), radiotherapy after total mastectomy in patients with tumor size 
greater than 5 cm and/or tumor that has spread to four or more axillary lymph nodes (NCCN, 
2006), chemotherapy drugs (e.g., taxanes, anthracyclines, and cyclophosphamide) in patients 
with lymph node positive breast cancer or those with tumors larger than 1 cm (NCCN, 2006, 
Maughan et al., 2010), hormonal therapies such as selective estrogen receptor modulators (e.g., 
tamoxifen) and aromatase inhibitors (e.g., anastrazole, letrozole, and exemestane) in patients 
with estrogen receptor-positive breast cancer (NCCN, 2006, Burstein et al., 2010, Maughan et 
al., 2010), and tissue-targeted therapies (e.g., trastuzumab) in women with Human Epidermal 
Growth Factor Receptor 2 (HER2) positive breast cancer (NCCN, 2006, Maughan et al., 2011).   
Receipt of breast cancer treatment, which is compliant with the established breast cancer 
treatment guidelines, is crucial for optimal survival in breast cancer patients (Herbert-Croteau et 
al., 2004, Maskarinec et al., 2011).  However, despite these treatment guidelines, studies have 
reported that up to 55% of the women with breast cancer do not receive treatment compliant with 
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these guidelines (Bloom et al., 2004, Landercasper et al., 2006, Foley et al., 2007, Worthington 
et al., 2008, Iyengar et al., 2010, Shirvani et al., 2011).   
An important first step towards improving the treatment of breast cancer patients is 
developing an understanding of factors affecting receipt of guideline-consistent breast cancer 
treatment.  Various patient and healthcare-related characteristics have been found to be 
associated with receipt of guideline-consistent breast cancer treatment in prior studies.   
Individual characteristics such as younger age (Ballard-Ballash et al., 1996, Haggstorm et al., 
2005, Voti et al., 2006, Anderson et al., 2008, Chagpar et al., 2008, Rosato et al., 2009, Jagsi et 
al., 2010, Chien et al., 2012), Caucasian race (Haggstorm et al., 2005, Voti et al., 2006, Smith et 
al., 2010, Freedman et al., 2011), being married (Voti et al., 2006), residence in a metropolitan 
area (Haggstorm et al., 2005, Worthington et al., 2008), possession of insurance (Voti et al., 
2006, Freedman et al., 2011), fewer comorbidities (Ballard-Barbash et al., 1996, Rosato et al., 
2009, Jagsi et al., 2010), and prior use of mammography (Smith et al., 2010) have been 
associated with receipt of guideline-consistent breast cancer treatment.  Hospital related 
characteristics, including number of breast cancer-related surgical procedures conducted 
annually (Rosato et al., 2009, Chien et al. 2012), membership in multiple National Cancer 
Institute-funded research networks (Laliberte et al., 2005), non-teaching status (Voti et al., 2006), 
and hospital size (Satariano et al., 1992, Grilli et al., 1994, Guadagnoli et al., 1998), have been 
found to positively impact receipt of guideline-consistent breast cancer treatment.  Healthcare 
access-related variables such as the number of primary care physicians and the number of 
radiologists in the healthcare service area have also been shown to be positively associated with 
receipt of guideline-consistent breast cancer treatment (Ballard-Ballash et al., 1996).   
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While these studies provide useful information, limited information currently exists about 
the impact of pre-existing mental illnesses on the receipt of guideline-consistent breast cancer 
treatment.  About one in four adults in the US have a mental illness and nearly 50% will develop 
at least one mental illness in their lifetime (Kessler et al., 2005, Reeves et al., 2011).  Due to 
health-related issues such as poor eating and sleeping habits, lack of exercise, indulgence in 
smoking, alcohol, and drug abuse, and impaired immune system, individuals with mental 
illnesses are more likely to develop comorbid physical conditions (Kendrick, 1996, Osborn, 
2001, Mitchell et al., 2009).  Higher incidence of breast cancer has been reported in individuals 
with mental illness as compared to those without any mental illness (McGinty et al., 2012).  The 
impairment of  cognitive, emotional, and/or behavioral functioning in patients with mental 
illnesses could affect their receipt of mental and physical healthcare services.   
A thorough review of the literature yielded only one study evaluating the impact of pre-
existing mental illnesses on receipt of guideline-consistent breast cancer treatment.  Goodwin et 
al. (2004) evaluated the effect of pre-existing depression on breast cancer treatment among 
elderly Medicare beneficiaries with breast cancer.  Women with pre-existing depression were 
19% more likely to receive treatment non-consistent with established standards of breast cancer 
care (simple mastectomy or breast-conserving surgery plus adjuvant irradiation for Stage 0, 
modified radical mastectomy or breast-conserving surgery with axillary dissection and adjuvant 
irradiation for Stage I or II, and chemotherapy for Stages III or IV) as compared to women 
without pre-existing depression.  While the work conducted by Goodwin et al. (2004) provided 
useful information, the authors did not consider the impact of other mental illnesses in the study.  
In addition, the authors only studied this relationship among elderly women.  
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Besides guideline-consistent breast cancer treatment, another treatment-related attribute, 
crucial for optimal health outcomes in breast cancer patients, is the healthcare utilization during 
breast cancer treatment.  Frequent contact with the healthcare system during breast cancer 
treatment in the form of regular physician office visits and necessary hospital stays is necessary 
for timely delivery of healthcare and prevention of unplanned hospital visits and ER visits.  
While factors such older age at diagnosis, higher educational level, lower quality of life, not 
having children, and receipt of hormonal therapy and chemotherapy have been found to be 
associated with healthcare utilization post diagnosis in breast cancer patients (Keyzer-Dekker et 
al., 2012, Roorda et al., 2012), no information is currently available about the impact of pre-
existing mental illnesses on healthcare utilization post diagnosis in breast cancer patients.   
The current study determined the impact of pre-existing mental illnesses on the receipt of 
guideline-consistent breast cancer treatment and breast cancer-related healthcare utilization 
among women Medicaid enrollees diagnosed with breast cancer.  Effect of mental illnesses, 
including mood disorders (e.g., bipolar affective disorders, dysthymic disorder, major depressive 
disorder, and adjustment reactions), psychotic disorders (e.g., schizophrenia, paranoid states, and 
non-organic psychoses), substance abuse and dependence disorders, and other mental disorders, 
on receipt of guideline-consistent breast cancer treatment (breast conserving surgery followed by 
radiation therapy or total mastectomy with or without radiation therapy for Stage I and II breast 
cancers and chemotherapy for Stages III and IV breast cancers) (NCCN, 2006) was evaluated in 
the study.  In addition, the impact of pre-existing mental illnesses on breast cancer-related 
healthcare utilization during the initial 12 months following diagnosis of breast cancer was 
determined.   
 
 64 
 
Methods 
Data source 
The current study used the data from the 2006-2008 Medicaid analytic extract (MAX) files.  The 
MAX files for 39 states (all states except Alaska, Hawaii, Maine, Missouri, Montana, North 
Dakota, Pennsylvania, South Dakota, Utah, Wisconsin, Wyoming, and District of Columbia) 
were used in this study.  The MAX files are created from the Medicaid Statistical Information 
System (MSIS) and are maintained by the Centers for Medicare and Medicaid service (CMS).  
Information about patient demographics, eligibility, and enrolment status was available through 
the MAX personal summary file.  Claims for inpatient services received by the recipients were 
provided through the MAX inpatient file, whereas information about the non-institutional 
services received by the Medicaid enrollees was made available through the MAX other therapy 
file.  Details about the prescription drugs dispensed to the recipients were provided through the 
MAX prescription drug file.  All the files were linked using a unique encrypted recipient 
identification number.  All data were made available to the researcher in a deidentified format.  
Study protocol was approved by the Institutional review board (IRB) at University of 
Mississippi.  Data use agreement (DUA) was obtained from CMS through Research Data 
Assistance Center (ResDAC). 
 
Study sample 
The target population for the study consisted of women Medicaid enrollees who were: (1) 
continuously enrolled in Medicaid during the years 2006-2008; (2) at least 18 years of age on 
January 01, 2006 and less than 65 years of age on December 31, 2008; and (3) newly diagnosed 
with breast cancer between January 01, 2007 and December 31, 2007.  Women less than 18 
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years of age were excluded from study analysis since breast cancer is rare in adolescent women.  
In addition, the study excluded women aged 65 years or more since Medicare is the primary 
payer in these individuals.  Dual eligibles, i.e., women aged less than 65 years enrolled in both 
Medicare and Medicaid, were also excluded from the study due to incomplete data in MAX files.  
Women newly diagnosed with breast cancer were identified using an algorithm developed by 
Solin et al. (1994).  As per this algorithm, a case of breast cancer was defined as a new case if the 
medical utilization data between January 01, 2007 and December 31, 2007 met one or more of 
the following six treatment-related criteria: (1) mastectomy (current procedural terminology 4
th
 
edition [CPT-4] codes of 19180-19240); (2) partial mastectomy with lymphadenectomy (CPT-4 
code of 19162); (3) excision (CPT-4 code of 19120, 19125, or 19126), breast biopsy (CPT-4 
code of 19100 or 19101), or partial mastectomy (CPT-4 code of 19160) plus lymphadenectomy 
(CPT-4 code of 38740 or 38745); (4) excision, breast biopsy, or partial mastectomy plus 
diagnosis of carcinoma (International Classification of Diseases, ninth revision, clinical 
modification [ICD-9-CM] codes of 174-174.9 or 233.0); (5) excision, breast biopsy, or partial 
mastectomy followed by radiation therapy (CPT-4 codes of 77261-77499); or (6) excision, 
breast biopsy, or partial mastectomy followed by chemotherapy (CPT-4 codes of 96400-96549).  
The date of the first record with a diagnosis of breast cancer (ICD-9-CM codes of 174, 233.0, 
238.3, and 239.3) for each breast cancer case was considered as the diagnosis date.  The medical 
records for the cases identified using Solin’s algorithm were monitored to determine if there 
were any breast cancer diagnosis prior to their initial diagnosis.  Only those cases without any 
prior medical record with a diagnosis of breast cancer were considered as incident cases.   
 
Measures 
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Receipt of guideline-consistent breast cancer treatment was determined based on compliance 
with the established guidelines for the treatment of breast cancer (NCCN, 2006).  Individuals 
diagnosed with stage I and II breast cancer, who received breast conserving surgery followed by 
radiation therapy or total mastectomy with or without radiation therapy, were considered as 
having received guideline-consistent breast cancer treatment.  Receipt of chemotherapy for stage 
III and IV breast cancer patients was considered as guideline-consistent breast cancer treatment.  
The observation period for measuring guideline-consistent breast cancer treatment was 12 
months post the diagnosis of breast cancer.  Breast conserving surgery was identified from the 
medical utilization data using CPT-4 codes of 19120-19126, 19160-19162, 19180, 19182, 19200, 
19220, 19240, 19260, 19271, 19272, 19290-19298, 19316-19396, and 19499 and ICD-9-CM 
procedure codes of 8520-8525, 8534-8536, 8541-8548, and 8663.  Total mastectomy was 
determined using CPT-4 code of 19180 and ICD-9-CM procedure codes of 85.41-85.44.  
Radiation therapy was determined based on CPT-4 codes of 77261-77418, 77427-77499, and 
77520-77525, ICD-9-CM procedure codes of 9221-9226, and ICD-9-CM diagnosis codes of 
V580, V661, and V671.  Use of chemotherapy was identified from the medical records with 
associated HCPCS codes of J8520 and J8521 (capecitabine), J8530 (oral cyclophosphamide), 
J9070-J9097 (cyclophosphamide), J9190 (5-flurouracil), J9260 and J9250 (methotrexate), J9201 
(gemcitabine), J9390 (vinorebine), J9265 (paclitaxel), J9170 (docetaxel), J9000 and J9001 
(doxorubicin), J9178 (epirubicin), J9045 (carboplatin), J9060 and J9062 (cisplatin), and J9355 
(trastuzumab), ICD-9-CM procedure code of 9225, and ICD-9-CM diagnosis code of V581, 
V662, and V672.  In addition, records from the prescription claims data with national drug codes 
(NDCs) for the above mentioned chemotherapy drugs were used to identify chemotherapy use 
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(Barron et al., 2008).  Guideline-consistent breast cancer treatment was considered as a 
dichotomous variable.   
Breast cancer-related healthcare utilization among recipients diagnosed with breast 
cancer was determined in the form of total number of breast cancer-related inpatient, outpatient, 
and emergency room (ER) visits during 12 months after the diagnosis of breast cancer.  An 
inpatient visit was considered to be breast cancer-related if the primary diagnosis code associated 
with the record was for breast cancer (ICD-9-CM code of 174, 233.0, 238.3, or 239.3).  
Outpatient and ER visits were considered to be breast cancer-related if the primary and/or 
secondary diagnosis code associated with the records were for breast cancer.  The 2007 and 2008 
MAX inpatient and other therapy files were used for identifying breast cancer-related healthcare 
utilization.  Observations listed in the inpatient file were considered as inpatient visits.  The 
MAX inpatient file is an event-level file and hence each observation was considered as one visit.  
Observations with place of service codes of 11 (office), 22 (outpatient hospital), 24 (ambulatory 
service center), 50 (federally qualified health center), 71 (state or local public health clinic), or 
72 (rural health clinic) and type of service codes of 08 (physicians), 10 (other practitioners), 11 
(outpatient hospital), 12 (clinic), 37 (nurse practitioner services) or those with procedure codes 
99201-99215, 99241-99245, 99354-99355, 99381-99429 in the other therapy file were classified 
as outpatient visits.  The MAX other therapy file is a claim-level file, and hence outpatient visits 
were defined based on the date of service.  If a recipient had one or more observations on a 
particular day that conformed to the above mentioned criteria, she was considered to have had an 
outpatient visit on that day.  Observations with place of service code of 23 in the other therapy 
file and those with revenue code of 450-459 or procedure codes of 99281-99285 in the other 
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therapy file or inpatient file were considered as ER visits.  Breast cancer-related inpatient, 
outpatient, and ER visits were considered as continuous variables. 
Pre-existing mental illnesses were identified based on the ICD-9-CM diagnosis codes 
associated with the medical records during 12 months prior to the date of diagnosis of breast 
cancer.  Four categories of mental illnesses were considered in this study: all mood disorders 
(ICD-9-CM codes 296.0, 296.1, 296.2, 296.3, 296.4, 296.5, 296.6, 296.7, 296.80, 296.81, 
296.89, 296.9, 300.4, 301.12, 301.13, 309.0, 309.1, 309.4, 311), all psychotic disorders (ICD-9-
CM codes 293.81, 293.82, 295, 297, 298), substance abuse and dependence disorders (ICD-9-
CM codes 291.0-291.1, 291.3-291.9, 292, 303, 304, 305), and other mental disorders that did not 
fall into the above categories (ICD-9-CM codes 290.00-319.99) (Baillargeon et al., 2011).  
Recipients with ICD-9-CM codes for mental illnesses in any position on the records in the MAX 
inpatient and other therapy files were considered as having a mental illness. 
 Other variables included in the study were age at diagnosis, race, the type of 
reimbursement system, breast cancer stage at diagnosis, Charlson comorbidity index (CCI), 
location of residence, state of residence, and the number of outpatient visits in the 12 months 
prior to diagnosis of breast cancer.  Age at diagnosis was considered as a continuous variable.  
Race was categorized into white, black, Hispanic or Latino, Asian, Native Hawaiian or other 
Pacific islander, American Indian or Alaskan Native, and others (consisting of more than one 
race and unknown race).  The type of reimbursement system consisted of categories of FFS only 
(recipients who were enrolled in FFS Medicaid during 2006-2008) and managed care (recipients 
who were enrolled in Medicaid managed care for at least one month during 2006-2008).  The 
stage of breast cancer at diagnosis was identified using an algorithm developed by Yuen et al. 
(2006), which is based on ICD-9-CM codes.  The breast cancer staging criteria stated in Yuen’s 
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algorithm have been listed in Appendix 1.  The comorbidity profile of the study sample was 
measured using CCI (D’Hoore adaptation).  CCI was calculated based on the medical records of 
the recipients during the period of 12 months prior to breast cancer diagnosis.  Mental illnesses 
were excluded from CCI calculation.  The state of residence consisted of 39 categories.  The 
location of residence was categorized as metropolitan, suburban, rural, and unknown and was 
defined for each recipient based on the United States Department of Agriculture (USDA) rural-
urban continuum codes: metropolitan location (codes 0-3), suburban location (codes 4-5), and 
rural location (codes 6-9).  The rural-urban continuum codes were determined based on the 
Federal Information Processing Standard (FIPS) code for the county of residence listed for each 
recipient in the 2006 MAX personal summary file.  The number of outpatient visits during 12 
months prior to the date of diagnosis of breast cancer was calculated based on records in the 
MAX other therapy files and was considered as a continuous variable. 
 
Statistical analysis 
Bivariate analyses were conducted for comparison of breast cancer patients with and without 
mental illnesses using chi-square tests for categorical variables and Student t test for continuous 
variables including age at diagnosis and CCI.  Wilcoxon rank sum test was used for the 
comparison of number of outpatient visits during 12 months prior to breast cancer diagnosis 
between breast cancer patients with mental illnesses and those without mental illnesses.  Means 
and standard deviations were reported for continuous variables and frequencies and percentages 
were reported for categorical variables.  Hierarchical logistic regression was used to determine 
the impact of pre-existing mental illnesses on the receipt of guideline-consistent breast cancer 
care.  Unadjusted and adjusted analyses were performed.  Odds ratios and 95% confidence 
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intervals were reported.  The impact of pre-existing mental illnesses on breast cancer-related 
healthcare utilization was examined using mixed effects Poisson regression or negative binomial 
regression. Unadjusted and adjusted analyses were performed.  The decision about using Poisson 
or negative binomial regression was based on the dispersion parameter (chi-square/degrees of 
freedom) observed after fitting the Poisson regression model.  Poisson regression was used in 
cases where the dispersion parameter was ~1, whereas negative binomial regression was used if 
the value of the dispersion parameter was found to be greater than 1.  Separate models were 
fitted with breast cancer-related inpatient, outpatient, and ER visits as the dependent variables.  
Incident rate ratios and 95% confidence intervals were reported.  Apart from measuring the 
impact of any pre-existing mental illness, separate models were fitted for the individual 
categories of pre-existing mental illness (mood disorders, psychotic disorders, substance abuse 
and dependence disorders, and other mental disorders).  All the covariates mentioned earlier 
were adjusted for in each of the models.  The random effects of the state and county of residence 
were included in all the models.  All analyses were performed using Statistical Analysis System 
(SAS) version 9.2 (SAS Institute Inc., Cary, NC).  The SAS procedure PROC GLIMMIX was 
used for fitting the multivariable models.    
 
Results 
The socio-demographic and clinical characteristics of the study sample are presented in Table 
3.1.  We identified 2,142 incident cases of breast cancer in the Medicaid population in the 
calendar year 2007.  Of these, approximately 42.5% were white and 25.2% were black.  Nearly 
92% of the recipients were enrolled in Medicaid managed care for at least one month during 
2006-2008.  Majority of the respondents (81.7%) lived in metropolitan areas.  Most (71.2%) 
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were diagnosed with stage I cancer.  The mean age at diagnosis of the sample was 50.41 years 
(±8.58).  The mean CCI was 1.12 (±1.68).  The mean number of outpatient visits during 12 
months prior to breast cancer diagnosis was 12.45 (±11.59).  Of the 2,142 incident breast cancer 
cases, roughly 38% (N = 806) had a pre-existing mental disorder.  The baseline demographic and 
clinical characteristics of breast cancer cases with and without mental disorders are presented in 
Table 3.1.  The mean age of recipients with mental illnesses was higher than those without any 
mental illness (50.86 years [±8.06] vs. 50.12 years [±8.89], p = 0.047).  A greater percentage of 
recipients with mental illnesses were white (52.51% vs. 35.99%, p < 0.0001) as compared to 
those without any mental disorders, whereas the percentage of blacks (27.57% vs. 21.41%, p < 
0.0001), Hispanics/Latinos (13.40% vs. 8.73%, p < 0.0001), and Asians (6.20% vs. 0.96%, p < 
0.0001) was greater in recipients without any pre-existing mental disorders as compared to those 
without at least one pre-existing mental disorder.  A higher proportion of recipients with pre-
existing mental illnesses were enrolled in Medicaid managed care for at least one month during 
2006-2008 as compared to those without any pre-existing mental illness (12.80% vs. 7.20%, p < 
0.0001).  Greater percentage of recipients without any pre-existing mental illness resided in 
metropolitan areas as compared to those with a pre-existing mental illness (83.92% vs. 81.14%, p 
= 0.0042).  No statistically significant difference was observed in the breast cancer stage at 
diagnosis between recipients with and without pre-existing mental illnesses.  The mean CCI was 
higher in recipients with mental illnesses than those without any mental illness (1.27 [±1.69] vs. 
1.02 [±1.67], p = 0.0007).  The mean number of outpatient visits during 12 months prior to breast 
cancer diagnosis was higher in recipients with one or more mental illnesses than those without 
any mental illness (15.64 [±12.94] vs. 10.41 [±10.13], p < 0.0001). 
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Table 3.1. Demographic and clinical characteristics of the study sample 
Characteristic 
All (N = 2,142) 
No mental 
disorder (N = 
1,306) 
Any mental 
disorder (N = 
806) 
p 
Age at diagnosis, 
Mean (SD) 
50.41(8.58) 
50.12(8.89) 50.86(8.06) 0.047 
Race, N (%)    < 0.0001 
White 909 (42.44) 470 (35.99) 439 (52.51)  
Black 539 (25.16) 360 (27.57) 179 (21.41)  
Hispanic or Latino 248 (11.58) 175 (13.40) 73 (8.73)  
Asian 89 (4.15) 81 (6.20) 8 (0.96)  
Native Hawaiian or 
other Pacific 
islander 
36 (1.68) 22 (1.68) 14 (1.67) 
 
American Indian or 
Alaskan native 
26 (1.21) 16 (1.23) 10 (1.20) 
 
Others 295 (13.77) 182 (13.94) 113 (13.52)  
Type of 
reimbursement system 
 
  
< 0.0001 
FFS only 201 (9.38) 94 (7.20) 107 (12.80)  
Managed care
a
 1,941 (90.62) 1,212 (92.80) 729 (87.20)  
Location, N (%)    0.0042 
Metropolitan 1,750 (81.70) 1,096 (83.92) 654 (81.14)  
Suburban 136 (6.35) 72 (5.51) 64 (7.94)  
Rural 225 (10.50) 125 (9.57) 100 (12.41)  
Unknown 31 (1.45) 13 (1.00) 18 (2.23)  
Stage, N (%)     0.0564 
0 46 (2.15) 28 (2.14) 18 (2.15)  
I 1525 (71.20) 904 (69.22) 621 (74.28)  
II 378 (17.65) 239 (18.30) 139 (16.63)  
III 14 (0.65) 10 (0.77) 4 (0.48)  
IV 179 (8.36) 135 (9.57) 54 (6.46)  
CCI, Mean (SD) 1.12 (1.68) 1.02 (1.67) 1.27 (1.69) 0.0007 
Number of physician 
visits during 12 
months prior to breast 
cancer diagnosis 
12.45 (11.59) 10.41 (10.13) 15.64 (12.94) < 0.0001 
SD: standard deviation 
FFS: fee-for-service 
a
The category managed care comprised of recipients enrolled in Medicaid managed care for at 
least one month during the study period (2006-2008) 
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The results of hierarchical logistic regression analyses conducted to determine the impact 
of pre-existing mental illnesses on receipt of guideline-consistent breast cancer treatment have 
been presented in Table 3.2.  In the multivariable analyses, recipients with one or more pre-
existing mental illnesses were found to be 20.7% less likely to receive guideline-consistent breast 
cancer treatment (adjusted odds ratio [AOR] = 0.793, 95% confidence interval [CI] = 0.646 – 
0.973) as compared to those without any mental illness.  In terms of individual mental illness 
categories, recipients with mood disorders were 24.7% less likely to receive guideline-consistent 
breast cancer treatment (AOR = 0.753, 95% CI = 0.585 – 0.970) as compared to those without 
any mental illness.  Recipients with other mental disorders were 31.7% less likely to receive 
guideline-consistent breast cancer treatment (AOR = 0.683, 95% CI = 0.531 – 0.879) as 
compared to those without any mental illness.  There was no statistically significant difference in 
the odds of receiving guideline-consistent breast cancer treatment between recipients with 
psychotic disorders and substance abuse and dependence disorders and those without any pre-
existing mental disorders. 
 
Table 3.2. Hierarchical logistic regression for determination of impact of pre-existing 
mental illnesses on guideline-consistent breast cancer treatment 
 Odds ratio 
Mental illness Unadjusted Adjusted 
No mental illness Reference Reference 
Any mental illness 0.806 (0.673 – 0.967) 0.793 (0.646 – 0.973) 
Mood disorders 0.764 (0.602 – 0.970) 0.753 (0.585  – 0.970) 
Psychotic disorders 0.977 (0.667 – 1.431) 0.939 (0.635 – 1.390) 
Substance abuse and 
dependence disorders 
0.743 (0.526 – 1.051) 0.805 (0.559 – 1.159) 
Other mental disorders 0.688 (0.542 – 0.873) 0.683 (0.531 – 0.879) 
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The results of Poisson/negative binomial regression analyses conducted to determine the 
impact of pre-existing mental illnesses on utilization of breast cancer-related inpatient services 
have been presented in Table 3.3.  In the multivariable analyses, no statistically significant 
differences were found in terms of number of inpatient visits between recipients with and 
without any pre-existing mental illnesses.  Similar results were obtained in the analyses 
conducted to determine the impact of individual mental illness categories on breast cancer-
related inpatient utilization.  Table 3.4 represents the results of Poisson/negative binomial 
regression analyses conducted to determine the impact of pre-existing mental illnesses on breast 
cancer-related outpatient visits.  In the multivariable analyses, recipients with one or more pre-
existing mental illnesses had 8.3% lesser number of outpatient visits (adjusted incident rate ratio 
[AIRR] = 0.917, 95% CI = 0.892 – 0.942) as compared to those without any mental illness.  The 
analyses conducted to determine the impact of individual mental illness categories on breast 
cancer-related outpatient utilization yielded similar results.  Recipients with pre-existing mood 
disorders had 7.3% lesser number of outpatient visits (AIRR = 0.927, 95% CI = 0.897 – 0.958) 
as compared to those without any mental illness.  Recipients with psychotic disorders had 17.1% 
lesser number of outpatient visits (AIRR = 0.829, 95% CI = 0.784 – 0.877) as compared to those 
without any mental illness.  Recipients with substance abuse and dependence disorders had 8.5% 
lesser number of outpatient visits (AIRR = 0.915, 95% CI = 0.866 – 0.966) as compared to those 
without any mental illness.  The number of outpatient visits was 7.4% (AIRR = 0.926, 95% CI = 
0.894 – 0.958) lesser among recipients with other mental illnesses as compared to recipients 
without any pre-existing mental illness.  
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Table 3.3. Mixed effects Poisson/negative binomial regression for determination of impact 
of pre-existing mental illnesses on breast cancer-related inpatient visits  
 Incident rate ratio 
Mental illness Unadjusted Adjusted 
No mental illness Reference Reference 
Any mental illness 0.932 (0.804 – 1.081) 0.993 (0.851 – 1.159) 
Mood disorders 0.851 (0.710 – 1.020) 0.906 (0.749 – 1.097) 
Psychotic disorders 0.943 (0.712 – 1.242) 1.001 (0.753 – 1.330) 
Substance abuse and 
dependence disorders 
1.034 (0.800 – 1.337) 1.147 (0.877 – 1.500) 
Other mental disorders 0.990 (0.828 – 1.184) 1.060 (0.880 – 1.278) 
 
 
Table 3.4. Mixed effects Poisson/negative binomial regression for determination of impact 
of pre-existing mental illnesses on breast cancer-related outpatient visits  
 Incident rate ratio 
Mental illness Unadjusted Adjusted 
No mental illness Reference Reference 
Any mental illness 0.882 (0.860 – 0.905) 0.917 (0.892 – 0.942) 
Mood disorders 0.879 (0.852 – 0.908) 0.927 (0.897 – 0.958) 
Psychotic disorders 0.792 (0.750 – 0.837) 0.829 (0.784 – 0.877) 
Substance abuse and 
dependence disorders 
0.835 (0.792 – 0.880) 0.915 (0.866 – 0.966) 
Other mental disorders 0.908 (0.879 – 0.938) 0.926 (0.894 – 0.958) 
 
 
The results of Poisson/negative binomial regression analyses conducted to determine the 
impact of pre-existing mental illnesses on utilization of breast cancer-related emergency room 
services have been presented in Table 3.5.  In the multivariable analyses, recipients with any pre-
existing mental illnesses had 15.8% lesser number of emergency room visits (AIRR = 0.842, 
95% CI = 0.709 – 0.999) as compared to those without any mental illness.  No statistically 
significant differences were observed in the number of emergency room visits between recipients 
belonging to individual mental illness categories and those without any mental illnesses.  
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Table 3.5. Mixed effects Poisson/negative binomial regression for determination of impact 
of pre-existing mental illnesses on breast cancer-related emergency room visits  
 Incident rate ratio 
Mental illness Unadjusted Adjusted 
No mental illness Reference Reference 
Any mental illness 0.744 (0.636 – 0.870) 0.842 (0.709 – 0.999) 
Mood disorders 0.769 (0.632 – 0.935) 0.978 (0.790 – 1.209) 
Psychotic disorders 0.704 (0.482 – 1.030) 0.667 (0.431 – 1.031) 
Substance abuse and 
dependence disorders 
0.795 (0.566 – 1.119) 0.749 (0.508 – 1.103) 
Other mental disorders 0.936 (0.787 – 1.113) 1.221 (0.850 – 1.752) 
 
Discussion 
Receipt of healthcare conforming to the established breast cancer treatment guidelines is crucial 
for optimal health outcomes in breast cancer patients.  However, it has been reported that more 
than two-fifth of the breast cancer patients do not receive the recommended healthcare.  An 
understanding of factors affecting breast cancer treatment consistent with the established 
standards is important for planning steps towards eliminating disparities in the treatment of 
breast cancer patients.  The current study advances the knowledge about factors affecting 
guideline-consistent breast cancer treatment by examining the impact of pre-existing mental 
illnesses on the receipt of guideline-consistent breast cancer treatment among Medicaid enrollees 
diagnosed with breast cancer.  In addition, the impact of pre-existing mental illnesses on breast 
cancer-related healthcare utilization (inpatient, outpatient, and ER visits) among newly 
diagnosed cases of breast cancer in the Medicaid population was determined.  Although a 
previous study had determined the impact of depression on guideline-consistent breast cancer 
treatment in elderly breast cancer patients (Goodwin et al., 2004), the current study is the first to 
evaluate the impact of all major mental illnesses on guideline-consistent breast cancer treatment.  
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Also, this is the first study to determine the impact of pre-existing mental illnesses on healthcare 
utilization in breast cancer patients.   
Recipients with a pre-existing mental illness were 20.7% less likely to receive guideline-
consistent breast cancer treatment as compared to recipients without any pre-existing mental 
illness.  Similar results were obtained in the analyses conducted to determine the impact of 
individual mental illness categories on receipt of guideline-consistent breast cancer treatment.  
The odds ratios did not reach statistical significance for psychotic disorders and substance abuse 
and dependence disorders, which could be due to the low statistical power given the low sample 
size in these groups.  Similar to our study, Goodwin et al. (2004) found that pre-existing 
depression was associated with 19% higher odds of non-guideline-consistent breast cancer 
treatment in their study of elderly breast cancer patients.  Studies in other cancers (Baillargeon et 
al., 2011, Boyd et al., 2012) and other disease areas (Druss et al., 2000, Frayne et al., 2005) have 
found negative association between pre-existing mental illnesses and guideline-consistent 
treatment.  Various patient- and provider-level characteristics can explain the negative 
association between presence of pre-existing mental illnesses and receipt of guideline-consistent 
breast cancer treatment observed in our study.  Impaired cognitive ability and poor 
communication skills in patients with mental illnesses could be responsible for less 
understanding of the treatment regimen.  Social isolation and listlessness could lead to lack of 
motivation to undergo treatments.  Disorganized thought processes could hinder the receipt of 
follow-up treatments (Baillargeon et al., 2011).  Patients with conditions such as paranoia, 
delirium, and dementia can wrongly perceive certain established treatments as life-threatening 
and thereby not consent their receipt (Mitchell et al., 2009, Lawrence and Kisely, 2010, 
Baillargeon et al., 2011).  In terms of provider-level factors, the stigma associated with the 
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treatment of patients with mental illnesses could cause providers to treat patients with mental 
illnesses differently as compared to patients without mental illnesses.  Also, physicians providing 
breast cancer treatment to patients with mental illnesses may not have time and/or skills to 
provide care to these patients (Phelan et al., 2002, Mitchell et al., 2009, Howard et al., 2010, 
Lawrence and Kisely, 2010, Chadwick et al., 2012).   
 Interesting results emerged from the multivariable regression analyses conducted to 
determine the impact of pre-existing mental illnesses on breast cancer-related healthcare 
utilization.  The association between presence of any pre-existing mental illnesses and breast 
cancer-related inpatient utilization was not statistically significant.  Similar results were obtained 
in the analyses examining the impact of individual mental illness categories on breast cancer-
related inpatient utilization.  However, a negative association was observed between presence of 
pre-existing mental illnesses and breast cancer-related outpatient visits.  The results were 
consistent for the composite variable of any pre-existing mental illnesses as well as the 
individual mental illness categories.  Most of the breast cancer treatments including surgical 
treatments and systemic adjuvant therapies are provided in outpatient settings due to 
technological developments in breast cancer treatment.  In general, only a few patients 
undergoing mastectomies and axillary lymph node dissections are treated in inpatient facilities 
(Russo et al., 2006).  This fact was also evident in this study with outpatient visits accounting for 
over 96% of the breast cancer-related healthcare use.  Also, only ~29.4% of the study sample had 
inpatient visits and the average number of inpatient visits among these recipients was 1.30 
(±0.60).  Considering these facts, the negative association between pre-existing mental illnesses 
and breast cancer-related outpatient visits observed in this study is indicative of the disparities 
experienced by breast cancer patients with pre-existing mental illnesses in terms of breast 
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cancer-related healthcare utilization.  It is likely that lower number of outpatient visits among 
women with breast cancer with pre-existing mental illnesses contribute towards their lack of 
guideline-consistent treatment.  Not undergoing regular office visits may negatively impact their 
treatment. 
Negative association was observed between presence of any pre-existing mental illnesses 
and utilization of breast cancer-related emergency room services.  Though unexpected, this 
finding may be explained by the possibility of lower incidence of treatment-related toxicities 
among those with pre-existing mental illnesses due to lower use of breast cancer treatments as 
compared to those without any pre-existing mental illness.  
The findings of this study have important practical implications.  The negative 
association between pre-existing mental illnesses and guideline-consistent breast cancer 
treatment and breast cancer-related healthcare utilization observed in this study emphasizes the 
need for more focused care of breast cancer patients with mental illnesses.  Strategies that rectify 
the negative effects of mental illnesses such as physician counseling, healthcare skills training, 
peer-led counseling and help in accessing healthcare, and support from family members could be 
helpful in reducing the healthcare disparities in these individuals (Lawrence and Kisely, 2010).  
Provision of integrated healthcare by involvement of mental health professionals during the 
breast cancer treatment phase could also be helpful in improving breast cancer treatment in these 
individuals.  This could be done by having the mental health professionals visit the concerned 
oncologist/physician during the patient visits or appointing case managers, who serve as a liaison 
between the specialties and co-ordinate the treatment of the patient (Lawrence and Kisely, 2010).   
 The current study had a few limitations.  Coding errors are possible while processing of 
administrative claims, which could have impacted the results of the study.  Individuals enrolled 
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in both Medicare and Medicaid were not included in the study since Medicare is the primary 
payer for these individuals and complete information about their medical care is not contained in 
the MAX files.  Therefore, the results obtained from this study are not representative of the entire 
Medicaid population in the states included in the study.  The incident cases of breast cancer and 
cancer stage were identified using algorithms developed by Solin et al. (1994) and Yuen et al. 
(2011).  Though these algorithms have been associated with favorable measurement properties in 
different patient populations, they have not been validated in the Medicaid population.  Mental 
illnesses were identified using medical claims data and ICD-9-CM diagnostic codes, which 
might have underestimated the true prevalence, since physicians often underrecognize some of 
the mental illnesses such as depression and dementia (Davidson et al., 1999, Raji et al., 2008, 
Baillargeon et al., 2011).  Further, we did not consider the role of medication (mental health-
related) adherence on receipt of guideline-consistent breast cancer treatment.  While several 
studies have used medical records during two years to identify mental illnesses (Goodwin et al., 
2004, Frayne et al., 2005, Baillargeon et al., 2011), we used medical records during the one year 
period prior to breast cancer diagnosis for determining the prevalence of mental illness.  The 
occurrence of mental illness among women with breast cancer may therefore be underreported in 
this study.  Some of the established breast cancer treatment guidelines, including use of 
chemotherapy for lymph node-positive breast cancer, endocrine therapies for estrogen receptor-
positive cancers, and tissue-targeted therapies for Human Epidermal Growth Factor Receptor 2-
positive breast cancer, were not considered while determining guideline-consistent breast cancer 
treatment due to unavailability of information in the MAX files.   
 This study determined the impact of pre-existing mental illnesses on receipt of guideline-
consistent breast cancer treatment and breast cancer-related healthcare utilization using 
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multistate Medicaid data.  Negative association was observed between presence of pre-existing 
mental illnesses and guideline-consistent breast cancer treatment.  The association between pre-
existing mental illnesses and breast cancer-related inpatient utilization was found to be 
statistically insignificant, whereas negative association was observed between pre-existing 
mental illnesses and breast cancer-related outpatient utilization.  The results were found to be 
consistent across different mental illness categories (any mental disorder, mood disorders, 
psychotic disorders, substance abuse and dependence disorders, and other mental disorders) for 
the most part.  Negative association was observed between presence of any pre-existing mental 
illness and breast cancer-related emergency room visits, whereas the results concerning the 
association between individual mental illness categories and breast cancer-related emergency 
room visits were statistically non-significant.  The results of this study highlight the disparities 
experienced by newly diagnosed breast cancer patients with pre-existing mental illnesses both in 
terms of receipt of guideline-consistent breast cancer treatment and breast cancer-related 
healthcare utilization.  Future studies should examine the impact of pre-existing mental illnesses 
on survival in breast cancer patients.    
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CHAPTER 4 
FACTORS ASSOCIATED WITH REPEAT MAMMOGRAPHY SCREENING AMONG 
WOMEN ENROLLED IN MEDICAID 
Introduction 
Breast cancer screening enables early detection of breast cancer at an asymptomatic, preventable, 
and curable stage, and coupled with effective diagnostic procedures and optimal treatment 
patterns, improves the likelihood of survival (Perry et al., 2008).  Mammography screening, 
which involves imaging of the breast tissue using ionizing radiations such as X-rays, is currently 
the mainstay of breast cancer screening.  Findings from several randomized controlled studies 
have shown that mammography screening is associated with mortality reduction in the range of 
15-25% (Anderson et al., 1988, Bjurstam et al., 1997, Chu et al., 1988, Tabar et al., 1992, Tabar 
et al., 1995, Roberts et al., 1990).  Mammography screening technique has also been found to be 
cost-effective (Wolstenholme et al., 1998).  All leading medical organizations, including the 
American Cancer Society (ACS), the American College of Radiology (ACR), the American 
Congress of Obstetricians and Gynecologists (ACOG), the American Medical Association 
(AMA), the Society of Breast Imaging (SBI), the National Cancer Institute (NCI), and the United 
States Preventive Services Task Force (USPSTF), recommend mammography screening for 
women.  The USPSTF guidelines recommend biennial mammography screening for women aged 
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50 to 74 years, whereas the NCI guidelines call for mammograms every 1-2 years in women 
aged 40 years or more.  Other leading medical organizations, including the   ACS, the ACR, the 
AMA, the SBI, and the ACOG, recommend yearly mammograms in all women starting at the 
age of 40 years.  
 The national mammography screening rates in the US increased significantly from 30% 
in 1987 to 70.1% in 2000, post which they declined to 68.1% in 2005 (Breen et al., 2011, 
Chagpar et al., 2008, Zhou et al., 2010, Shi et al., 2011).  The decline in the screening rates has 
been attributed mainly to the decrease in hormone replacement therapy (HRT) use in the early 
2000s owing to a Women’s Health Initiative  report suggesting an association between long term 
HRT use and breast cancer (Breen et al., 2007, Wolf et al., 2009).  The decreasing trend in the 
mammography screening rates observed in the first half of the decade of the 2000s has not 
continued after 2005 (Breen et al., 2011).  The recently observed national mammography 
screening rate of 72.4% in the year 2010 was greater than the 70% goal mentioned in the Healthy 
people 2010 objectives (Klabunde et al., 2012).  Despite these improvements in the 
mammography screening rates over the years, the rate of regular mammography screening 
(generally defined as receipt of mammograms every one-two years) continues to be low.  It has 
been reported that less than 50% of the women undergo mammography screening regularly 
(Clark et al., 2003, Rakowski et al., 2006, Gierisch et al., 2009).  Getting routinely screened with 
mammograms is important for greatest population-level benefits in terms of reduced morbidity 
and mortality.  Previous studies have reported that getting routinely screened with mammograms 
is associated with earlier detection of breast cancer and improved survival as compared to 
infrequent or no mammography screening (Freedman et al., 2003, Moss et al., 2006, Hellquist et 
al., 2010).   
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An understanding of the factors affecting receipt of routine mammography is a critical 
first step in order to design strategies aimed at increasing the rates of regular mammography 
screening.  Various socio-demographic, healthcare-related, and psychological factors have been 
found to be associated with regular mammography screening in the previous studies.  Individual 
characteristics such as Caucasian race (Song et al., 1998, Yood et al., 1999, Sabogral et al., 2001, 
Strzelczyk and Dignan, 2002), higher education (Strzelczyk and Dignan, 2002, Rahman et al., 
2003, Raucher et al., 2005, Litaker et al., 2007), being married (Yood et al., 1999, Coughlin et 
al., 2004, Borrayo et al., 2009), residence in metropolitan areas (Sabogral et al., 2001), higher 
income (Phillips et al., 1998, Yood et al., 1999, Sabogral et al., 2001, Rakowski et al, 2006, 
Litaker et al., 2007), age in the range of 50-59 years (Coughlin et al., 2004, Borrayo et al., 2009, 
Gierisch et al., 2010), non-indulgence in smoking and indulgence in alcohol (Coughlin et al., 
2004, Rosenberg et al., 2005, Rakowski et al., 2006, Borrayo et al., 2009), family history of 
breast cancer (Lerman et al., 1990, Strzelczyk and Dignan, 2002, Bobo et al., 2004, Rosenberg et 
al., 2005, Borraryo et al., 2009, Gierisch et al., 2010, Vyas et al., 2012), and possession of health 
insurance (Cummings et al., 2000, Strzelczyk and Dignan, 2002, Coughlin et al., 2004, Litaker et 
al., 2007) have been found to be positively associated with routine receipt of breast cancer 
screening.   Factors related to healthcare use such as having a visit to a physician and 
obstetricians/gynecologists (Taylor et al., 1995, Coughlin et al., 2004, Wu et al., 2007), regular 
care from a healthcare provider (Bobo et al., 2004, Rakowski et al., 2006, Litaker et al., 2007), 
use of other preventive procedures such as cervical cancer screening tests, colorectal cancer 
screening tests, and influenza shots (Phillips et al., 1998, Cummings et al., 2000, Raucher et al., 
2005, Rosenberg et al., 2006, Wu et al., 2007), prior mammography or breast biopsy (Song et al., 
1998, Bobo et al., 2004), and use of hormone replacement therapy (Bobo et al., 2004, Borrayo et 
 91 
 
al., 2009) have been found to be positively impact regular mammography screening.   
Psychological factors such as perceived susceptibility towards breast cancer, perceived severity 
of breast cancer, and perceived benefits of mammography screening have also been reported to 
positively impact routine mammography screening (Lerman et al., 1990, Lee et al., 1995, Taylor 
et al., 1995, Halabi et al., 2000, Rakowski et al., 2006).  Studies have also found factors related 
to healthcare access such as health maintenance organization (HMO) penetration rate, number of 
primary care physicians and obstetricians/gynecologists, number of mammography screening 
facilities, and level of education and income in the area to be positively associated with routine 
mammography (Phillips et al., 1998, Engelman et al. 2002, Baker et al., 2004, Benjamins et al., 
2004, Litaker et al., 2007, Coughlin et al., 2008, Akinyemiju et al., 2012). 
 Limited information is currently available about the factors associated with regular 
mammography screening among Medicaid enrollees.  Medicaid is a health insurance program 
that provides medical benefits to certain low-income adults and children, disabled individuals, 
and pregnant women in the US.  The Medicaid program covers nearly 60 million individuals and 
accounts for 16% of the national health spending (Kaiser Family Foundation [KFF]).  Compared 
to privately insured individuals, Medicaid beneficiaries are more likely to have poor general 
health status, more physical and mental chronic health conditions, and higher hospitalization and 
mortality rates (Cunningham et al., 2005, Holohan et al., 2003, KFF).  Medicaid enrollees are 
also likely to have lower access to quality healthcare and fewer family and community resources 
as compared to other insured individuals (Landon and Epstein, 1999, Piecoro et al., 2001, 
Rowland, 2005).  It has been reported that Medicaid enrollees are less likely to indulge in 
preventive healthcare services, including mammography screening, as compared to other insured 
individuals (Schuur et al., 2009, Government Accountability Office).   
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A few studies have examined the use of regular mammography screening and the 
associated factors in the Medicaid population (Weir et al., 2011, Bhanegaonkar et al., 2012).  
Weir et al. (2011) studied the routine mammography use among enrollees of five Medicaid 
managed care plans in Massachusetts.  The authors found that 63% of the women aged 40-64 
years received routine mammograms.  Various factors, including non-disability, older age, 
Hispanic race, number of comorbidities, non-indulgence in smoking and alcohol, severe mental 
illness, no case of domestic violence, lesser number of emergency room (ER) visits, and greater 
number of office visits during the study period, were found to be positively associated with 
regular mammography screening.  In another study, Bhanegaonkar et al. (2012) examined the 
mammography screening behaviors of women enrolled in West Virginia Medicaid fee-for-
service (FFS) program.  It was observed that 8.6% of the women aged 40-64 years demonstrated 
high persistence with mammography screening (8-10 mammograms during the period 1999-
2008).  Older age and residence in non-metro rural areas were associated with persistent receipt 
of mammograms in the bivariate analyses.  The authors, however, did not conduct any 
multivariable analyses to determine the factors associated with mammography screening 
persistence.  Though these studies provide useful information about regular mammography 
screening among Medicaid enrollees and the associated factors,  findings of both these studies 
may have limited generalizability since they only involved state-specific Medicaid recipients.  
Further, these studies included only FFS (Bhanegaonkar et al. [2012]) or managed care (Weir et 
al. [2011]) recipients.    
The current study builds on the work of Weir et al. (2011) and Bhanegaonkar et al. 
(2012) by determining the prevalence of repeat mammography screening and associated factors 
in a multistate Medicaid population.  Effect of individual characteristics including age, race, 
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number of outpatient visits during the study period, number of ER visits during the study period, 
use of hormone replacement therapy, and receipt of routine cervical cancer screening tests on 
repeat mammography screening was determined.  In addition, effect of neighborhood factors 
including those denoting healthcare access in the neighborhood such as number of primary care 
physicians, number of obstetricians/gynecologists, number of mammography screening facilities, 
and number of federally qualified healthcare centers per 10,000 women in the county of 
residence and neighborhood socio-demographic characteristics such as level of urbanization, 
percentage of population aged 25 or more with at least a high school diploma, and race/ethnicity 
composition of the county of residence on repeat mammography was studied.   
 
Methods 
Data source 
The primary source of data for this study was the 2006-2008 Medicaid analytic extract (MAX) 
files.  The MAX files for 39 states (all states except Alaska, Hawaii, Maine, Missouri, Montana, 
North Dakota, Pennsylvania, South Dakota, Utah, Wisconsin, Wyoming, and District of 
Columbia) were used for the purpose of the study.  MAX files are a set of person-level files 
developed mainly for the purpose of supporting research and policy analysis.  The MAX 
personal summary, inpatient, other therapy, and prescription drug files were used in this study.  
Information about demographic characteristics of the recipients including age, race, sex, and 
location of residence, monthly enrolment status, and medical utilization summaries was available 
through the MAX personal summary file.  Details about medical services received by the 
recipients in the hospital, ER, or office setting including cost to the recipients, amount 
reimbursed by Medicaid, service beginning and end date, diagnosis codes based on International 
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Classification of Diseases, ninth revision, clinical modification (ICD-9-CM), and procedure 
codes based on Current Procedural Terminology version 4 (CPT-4) or Healthcare Common 
Procedure Coding System (HCPCS) were made available through the MAX inpatient and other 
therapy files.  The prescription drug usage of the recipients was identified using the National 
Drug Code (NDC) in the MAX prescription drug file.  Identification of individual recipients was 
not possible in the MAX files in order to protect patient privacy.  All the files were linked using 
an encrypted recipient identification number. 
 The second source of data used in the study was the Area Resource File (ARF).  The 
2010-2011 ARF access system, which contains current and historical data, was used for the 
purpose of this study.  The ARF is managed by the United States Health Resources and Services 
Administration and contains information about health facilities, health professionals, measures of 
resource scarcity, health status, economic activity, health training programs, and socioeconomic 
and environmental characteristics for each of the counties in the US.  The information in the 
ARF is obtained from sources such as the Bureau of the Census, the American Hospital 
Association, the American Medical Association, and the Centers for Disease Control and 
Prevention.  The ARF also contains information about geographic codes including metropolitan-
micropolitan statistical area codes, typology codes, Federal Information Processing Standard 
(FIPS) codes, and economic area codes, based on which it can be linked to other datasets.  The 
ARF and the MAX personal summary file were linked using the FIPS codes.  Study protocol was 
approved by the institutional review board at the University of Mississippi under exempt status. 
 
Study sample 
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The target population for this study consisted of female Medicaid enrollees who were 
continuously enrolled in the Medicaid program during 2006-2008 and who were 40 years old or 
more on January 01, 2006 and less than 65 years old on December 31, 2008.  Since 
mammography screening has been recommended in women aged 40 or more by the ACS, the 
lower age limit for this study was 40 years.  Women aged 65 or more were excluded from the 
study, since Medicare is the primary payer in these individuals and hence their complete medical 
records are not available in the MAX files.  Women aged less than 65 years, who were enrolled 
in both Medicare and Medicaid, were also excluded from the study on account of incomplete 
data in the MAX files.  Although annual mammography screening is also recommended after the 
diagnosis and treatment of breast cancer, the focus of this study was on the use of mammography 
screening prior to breast cancer diagnosis.  Therefore, recipients with a diagnosis of breast cancer 
(recipients having medical claims with ICD-9-CM diagnosis codes of 174, 233.0, 238.3, or 
239.3) during the study period (2006-2008) were excluded from the study.  
 
Measures 
Repeat mammography screening was defined as receipt of two successive mammograms with a 
gap of 10-14 months.  Though ACS recommends annual mammograms starting at age 40 until a 
woman is in good health, a gap of 14 months was allowed between consecutive mammograms in 
the current study since the recipients can face constraints such as waiting times at the 
mammography facilities (Gierisch et al., 2010).  Moreover, a gap of at least 10 months was 
required between consecutive mammograms while determining repeat mammography use since 
mammograms within a span of nine months or less since the previous mammogram are generally 
follow-up or diagnostic mammograms (Yood et al., 1999, Gierisch et al., 2010).  The receipt of 
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mammography screening was ascertained from the CPT-4 code of 76092 (screening 
mammography, bilateral) and HCPCS code of G0202 (screening mammography producing 
direct digital image, bilateral).  Repeat mammography screening was determined based on the 
dates of receipt of mammograms.  Apart from a gap of 10-14 months between successive 
mammograms, an identical gap was required between the start of the study period i.e. January 
01, 2006 and the date of the first mammogram during the study period and between date of last 
mammogram during the study period and end of the study period i.e., December 31, 2008, for 
classifying recipients as having received repeat mammography.  Repeat mammography was 
considered as a dichotomous variable.  
Among the independent variables, age was considered as of January 01, 2006 (beginning 
of the study period) and was categorized into two groups: 40-49 years and 50-64 years.  Race 
was categorized as white, black, Hispanic or Latino, Asian, Native Hawaiian or other Pacific 
islander, American Indian or Alaskan Native, and others (consisting of more than one race and 
unknown race).  The number of outpatient visits and number of ER visits during the study period 
were determined from the 2006-2008 medical services claims data and were considered as 
continuous variables.  Use of hormone replacement therapy (HRT) was determined based on the 
prescription drug records of the recipients during 2006-2008.  Receipt of routine cervical cancer 
screening tests was defined based on the consensus guidelines from the ACS, the USPSTF, and 
the ACOG, which recommended Papanicolaou (Pap) test in women aged 30-65 years every 2-3 
years at the time of the study period (Jin et al., 2011).  Accordingly, the receipt of Pap test at 
least once during the study period was considered as routine cervical cancer screening.  Use of 
HRT and routine cervical cancer screening were considered as dichotomous variables.  
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In terms of neighborhood factors, level of urbanization of the counties was considered as 
a categorical variable and consisted of three categories: metropolitan, suburban, or rural.  The 
definition of level of urbanization was based on the United States Department of Agriculture 
(USDA) rural-urban continuum codes: metropolitan location (codes 0-3), suburban location 
(codes 4-5), and rural location (codes 6-9).  The rural-urban continuum codes were determined 
from the Federal Information Processing Standard (FIPS) code for the county of residence listed 
in the 2006 MAX personal summary file.  Other neighborhood factors, including number of 
primary care physicians, number of obstetricians/gynecologists, number of mammography 
screening facilities, and number of federally qualified healthcare centers per 10,000 women, 
percentage of the county population aged 25 or more with at least a high school diploma,  
percentage of the county population Hispanic, and percentage of the county population non-
Hispanic black (the latter two denoting the race/ethnicity composition of each county), were 
categorized into quartiles for the purpose of this study.  Information about the neighborhood 
factors was gathered from the 2010-2011 ARF access system.  Information concerning number 
of federally qualified healthcare centers, number of primary care physicians, and number of 
obstetricians/gynecologists and neighborhood demographic characteristics, including percentage 
of the county population aged 25 or more with at least a high school diploma, percentage of the 
county population Hispanic, and percentage of the county population non-Hispanic black was 
from the year 2006.  The latest available data (1994) was used in case of county-level 
mammography screening facilities. 
 
Statistical Analysis 
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Descriptive statistics were conducted to determine the characteristics of the study sample.  
Means and standard deviations were reported for continuous variables, whereas frequencies and 
percentages were reported for categorical variables.  In the context of the current study, 
recipients were nested within counties and counties were nested within states.  Hence, in order to 
take into account correlation within clusters as well as examine the effects of individual and 
neighborhood characteristics on repeat mammography screening, hierarchical logistic regression, 
a multilevel modeling procedure, was used in the study.   Bivariate analyses were conducted 
using unadjusted hierarchical logistic regression models with county and state as random effects.  
In order to determine the factors affecting repeat mammography screening, multivariable 
hierarchical logistic regression models were fitted with all the predictors as fixed effects and 
county and state as random effects.  Type of reimbursement system (categorized as FFS only 
[recipients who were enrolled in FFS Medicaid during 2006-2008] and managed care [recipients 
who were enrolled in Medicaid managed care for at least one month during 2006-2008]) was 
also included as a covariate in the multivariable logistic regression models.  Odds ratios and 95% 
confidence intervals were reported for the results of the hierarchical logistic regression analyses. 
Level of statistical significance (α) was considered to be 0.05.  All analyses were performed 
using Statistical Analysis System (SAS) version 9.2 (SAS Institute Inc., Cary, NC).  The SAS 
procedure PROC GLIMMIX was used for fitting the hierarchical logistic regression models.  
 
Results 
The study sample consisted of 1,029,836 women.  Table 4.1 presents the demographic, 
healthcare-related, and neighborhood characteristics of the study sample.  More than half of the 
study sample (53.60%) was 40-49 years of age.  Nearly 42% of the sample was white, 25% was 
 99 
 
black, and the remaining 33% were ethnic minorities such as Hispanics/Latinos, Asians, Native 
Hawaiian or other Pacific Islanders, and American Indians or Alaskan natives.  Roughly 1.19% 
of the population received repeat mammograms in accordance with established guidelines during 
the study period.  In terms of other healthcare-related characteristics, nearly 12% of the 
population received hormone replacement therapy.  Approximately 9% of the recipients 
underwent cervical cancer screening in accordance with established guidelines (at least one Pap 
test during the study period).  The average number of visits to outpatient centers during the study 
period was 31.42(±37.04) whereas the average number visits to emergency rooms was 
3.61(±8.15).  Majority of the sample (82.83%) resided in metropolitan counties.  The study 
recipients were uniformly distributed across quartiles of the other neighborhood measures 
including number of primary care physicians in the county per 100,000 women, number of 
obstetricians/gynecologists in the county per 100,000 women, number of federally qualified 
health centers per 100,000 women, number of mammography screening facilities per 100,000 
women, percentage of county population Hispanic, percentage of county population non-
Hispanic black, and percentage of county population with at least a high school diploma. 
 
Table 4.1. Study sample characteristics 
Characteristics N (%) 
Personal characteristics  
Age (years)  
40-49 551,949 (53.60) 
50-64 477,887 (46.40) 
Race  
White 428,573 (41.62) 
Black 258,527 (25.10) 
Hispanic or Latino 118,990 (11.55) 
Asian 51,853 (5.04) 
Native Hawaiian or other Pacific islander 18,413 (1.79) 
American Indian or Alaskan native 11,045 (1.07) 
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Others 142,435 (13.83) 
Repeat mammography screening  
Yes 12,212 (1.19) 
No 10,17,624 (98.81) 
Hormone replacement therapy  
Yes 118,892 (11.54) 
No 910,944 (88.46) 
Routine cervical cancer screening  
Yes 95,845 (9.31) 
No 933,991 (90.69) 
Number of outpatient visits during the study 
period, Mean (SD) 
31.42 (37.04) 
Number of emergency room visits during the 
study period 
3.61 (8.15) 
Neighborhood characteristics   
Number of primary care physicians per 
100,000 female population in the county 
 
1
st
 quartile (poorest) 257,602 (25.01) 
2
nd
 quartile 250,261 (24.30) 
3
rd
 quartile 256,881 (24.94) 
4
th
 quartile 265,092 (25.74) 
Number of obstetricians/gynecologists per 
100,000 female population in the county 
 
1
st
 quartile (poorest) 248,024 (24.08) 
2
nd
 quartile 253,329 (24.60) 
3
rd
 quartile 271,058 (26.32) 
4
th
 quartile 257,425 (25.00) 
Number of mammography screening facilities 
per 100,000 female population in the county 
 
1
st
 quartile (poorest) 271,623 (26.34) 
2
nd
 quartile 243,044 (23.60) 
3
rd
 quartile 265,625 (25.79) 
4
th
 quartile 249,904 (24.27) 
Number of federally qualified health centers 
per 100,000 female population in the county 
 
1
st
 quartile (poorest) 250,253 (24.30) 
2
nd
 quartile 265,543 (25.49) 
3
rd
 quartile 258,536 (25.10) 
4
th
 quartile 258,504 (25.10) 
Level of urbanization in the county  
Metropolitan 853,027 (82.83) 
Suburban 67,031 (6.51) 
Rural 109,778 (10.66) 
Percentage of county population Hispanic  
1
st
 quartile 257,691 (25.02) 
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2
nd
 quartile 257,665 (25.02) 
3
rd
 quartile 256,511 (24.91) 
4
th
 quartile (poorest) 257,969 (25.05) 
Percentage of county population non-
Hispanic black 
 
1
st
 quartile 257,447 (25.00) 
2
nd
 quartile 258,340 (25.09) 
3
rd
 quartile 256,376 (24.93) 
4
th
 quartile (poorest) 257,313 (24.99) 
Percentage of county population with at least 
a high school diploma 
 
1
st
 quartile (poorest) 257,073 (24.96) 
2
nd
 quartile 238,245 (23.23) 
3
rd
 quartile 276,053 (26.81) 
4
th
 quartile 257,465 (25.00) 
Total 10,29,836 (100) 
SD: standard deviation 
 
 
 Table 4.2 presents the results of the hierarchical logistic regression analyses conducted to 
determine the predictors of repeat mammography screening in the Medicaid population.  In the 
multivariable models, recipients aged 40-49 years were found to be less likely to receive repeat 
mammograms during the study period as compared to those aged 50-64 years (adjusted odds 
ratio [AOR] = 0.708, 95% confidence interval [CI] = 0.681 – 0.735).  Ethnic minorities including 
Hispanics/Latinos (AOR = 1.200, 95% CI = 1.119 – 1.288), Asians (AOR = 1.345, 95% CI = 
1.237 – 1.462), Native Hawaiian/ other Pacific islanders (AOR = 1.412, 95% CI = 1.232 – 
1.618), and others (AOR = 1.149, 95% CI = 1.083 – 1.219) were more likely than whites to 
receive repeat mammography screening.  American Indians/ Alaskan natives (AOR = 0.679, 
95% CI = 0.540 – 0.854) were less likely to undergo repeat mammography screening as 
compared to whites.  No statistically significant difference was observed in the odds of receiving 
repeat mammograms between blacks and whites (AOR = 1.015, 95% CI = 0.960 – 1.073).  The 
estimated odds of receiving repeat mammograms were lower in recipients who did not receive 
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hormone replacement therapy (AOR = 0.646, 95% CI = 0.615 – 0.678) and routine cervical 
cancer screening (AOR = 0.580, 95% CI = 0.550 – 0.613) during the study period as compared 
to those who received hormone replacement therapy and routine cervical cancer screening during 
the study period respectively.  Number of outpatient visits during the study period (AOR = 
1.005, 95% CI = 1.005 – 1.005) were positively associated, whereas number of emergency room 
visits during the study period (AOR = 0.978, 95% CI = 0.975 – 0.981) were negatively 
associated with receipt of repeat mammography screening.  In terms of association between 
neighborhood characteristics and repeat mammography screening, number of primary care 
physicians in the county per 100,000 women and number of federally qualified health centers in 
the county per 100,000 women emerged as the significant predictors.  Recipients residing in 
counties ranked lowest in terms of number of primary care physicians per 100,000 female 
population (1
st
 quartile) were more likely to receive repeat mammography screening as compared 
to those residing in counties ranked highest in terms number of primary care physicians per 
100,000 female population (4
th
 quartile) (AOR = 1.219, 95% CI = 1.013 – 1.468).  Recipients 
residing in counties ranked lowest in terms of number of federally qualified health centers per 
100,000 women were less likely to receive repeat mammography screening as compared to those 
residing in counties ranked highest in terms of number of federally qualified health centers per 
100,000 women (AOR = 0.900, 95% CI = 0.828 – 0.977).  
 
Table 4.2. Hierarchical logistic regression analysis for determining factors affecting repeat 
mammography screening 
Characteristics Odds ratio (95% confidence interval) 
 Unadjusted Adjusted 
Personal characteristics   
Age (years)   
40-49 0.860 (0.803 – 0.922) 0.708 (0.681 – 0.735) 
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50-64 Reference Reference 
Race   
Black 0.935 (0.886 – 0.986) 1.015 (0.960 – 1.073) 
Hispanic or Latino 1.123 (1.048 – 1.203) 1.200 (1.119 – 1.288) 
Asian 1.398 (1.288 – 1.519) 1.345 (1.237 – 1.462) 
Native Hawaiian or other 
Pacific islander 
1.484 (1.296 – 1.699) 
1.412 (1.232 – 1.618) 
American Indian or Alaskan 
native 
0.609 (0.484 – 0.768) 
0.679 (0.540 – 0.854) 
Others 1.137 (1.072 – 1.206) 1.149 (1.083 – 1.219) 
White Reference Reference 
Number of outpatient visits 
during the study period, Mean 
(SD) 
1.004 (1.004 – 1.005) 
1.005 (1.005 – 1.005) 
Number of emergency room 
visits during the study period 
0.989 (0.986 – 0.992) 
0.978 (0.975 – 0.981) 
Hormone replacement therapy   
No 0.577 (0.549 – 0.605) 0.646 (0.615 – 0.678) 
Yes Reference Reference 
Routine cervical cancer screening   
No 0.562 (0.533 – 0.593) 0.580 (0.550 – 0.613) 
Yes Reference Reference 
Neighborhood characteristics   
Number of primary care 
physicians per 100,000 female 
population in the county 
 
 
1
st
 quartile (poorest) 1.149 (1.001 – 1.320) 1.219 (1.013 – 1.468) 
2
nd
 quartile 1.138 (0.988 – 1.310) 1.164 (0.982 – 1.381) 
3
rd
 quartile 1.177 (1.013 – 1.366) 1.172 (0.999 – 1.375) 
4
th
 quartile Reference Reference 
Number of 
obstetricians/gynecologists per 
100,000 female population in the 
county 
 
 
1
st
 quartile (poorest) 1.027 (0.916 – 1.152) 0.923 (0.788 – 1.081) 
2
nd
 quartile 1.077 (0.952 – 1.218) 0.985 (0.847 – 1.146) 
3
rd
 quartile 1.086 (0.953 – 1.238) 1.031 (0.897 – 1.185) 
4
th
 quartile Reference Reference 
Number of mammography 
screening facilities per 100,000 
female population in the county 
 
 
1
st
 quartile (poorest) 0.936 (0.855 – 1.024) 0.938 (0.853 – 1.031) 
2
nd
 quartile 0.899 (0.803 – 1.007) 0.910 (0.810 – 1.023) 
3
rd
 quartile 0.954 (0.875 – 1.040) 0.961 (0.880 – 1.050) 
4
th
 quartile Reference Reference 
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Number of federally qualified 
health centers per 100,000 female 
population in the county 
 
 
1
st
 quartile (poorest) 0.910 (0.839 – 0.986) 0.900 (0.828 – 0.977) 
2
nd
 quartile 0.974 (0.872 – 1.089) 1.005 (0.892 – 1.132) 
3
rd
 quartile 0.934 (0.828 – 1.054) 0.936 (0.827 – 1.059) 
4
th
 quartile Reference Reference 
Level of urbanization in the 
county 
 
 
Metropolitan 0.987 (0.909 – 1.071) 0.999 (0.903 – 1.107) 
Suburban 1.066 (0.954 – 1.191) 1.069 (0.952 – 1.201) 
Rural Reference  
Percentage of county population 
Hispanic 
 
 
1
st
 quartile 0.985 (0.839 – 1.157) 1.087 (0.910 – 1.297) 
2
nd
 quartile 0.892 (0.770 – 1.033) 0.979 (0.831 – 1.152) 
3
rd
 quartile 0.866 (0.741 – 1.011) 0.938 (0.796 – 1.105) 
4
th
 quartile (poorest) Reference Reference 
Percentage of county population 
non-Hispanic black 
 
 
1
st
 quartile 1.072 (0.960 – 1.197) 1.052 (0.933 – 1.187) 
2
nd
 quartile 0.977 (0.872 – 1.095) 0.969 (0.862 – 1.088) 
3
rd
 quartile 0.898 (0.786 – 1.026) 0.906 (0.792 – 1.037) 
4
th
 quartile (poorest) Reference Reference 
Percentage of county population 
with at least a high school 
diploma 
 
 
1
st
 quartile (poorest) 1.010 (0.911 – 1.121) 0.942 (0.828 – 1.072) 
2
nd
 quartile 1.038 (0.944 – 1.141) 1.012 (0.912 – 1.123) 
3
rd
 quartile 1.035 (0.920 – 1.166) 1.040 (0.924 – 1.171) 
4
th
 quartile Reference Reference 
 
 
Discussion 
Routine mammography screening has been associated with early breast cancer detection and 
improved survival.  Guidelines from major medical organizations recommend annual 
mammograms in women aged 40 years or more.  However, it has been reported that more than 
half of the eligible women in the US do not undergo mammography screening regularly.  
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Knowledge about factors affecting routine mammography screening is crucial for devising 
strategies to increase regular mammography screening rates.  The current study contributes to the 
literature concerning factors affecting routine mammography screening by determining the 
factors affecting repeat mammography screening among Medicaid enrollees.  The impact of 
various recipient and neighborhood characteristics on repeat mammography screening was 
determined.  To the best of our knowledge, this is the first study to determine prevalence of 
routine mammography screening and the associated factors in the national Medicaid population.  
Only 1.19% of the study sample received repeat mammograms as per the recommended 
guidelines during the study period.  Our estimate of routine mammography screening rate is 
lower than the rates reported in previous studies examining routine mammography screening in 
the Medicaid population (Weir et al., 2011, Bhanegaonkar et al., 2012).  In their study of 
mammography use in beneficiaries of five Medicaid managed care plans in Massachusetts, Weir 
et al. (2011) found 63% of women aged 40-64 years to have received routine mammograms (at 
least one mammogram during the study period of 2005-2006).  Bhanegaonkar et al. (2012) 
studied mammography screening practices of women enrolled in West Virginia FFS Medicaid 
program and found 8.6% of the women aged 40-64 years to have received routine mammograms 
(8-10 mammograms during the period 1999-2008).  The differences in our findings and those of 
Weir et al. (2011) and Bhanegaonkar et al. (2012) could be attributed to differences in study 
settings and also the definition of routine mammography screening.  When we made our routine 
mammography screening criteria similar to that of Weir et al. (2011), who defined routine 
mammography as once every two years, the routine mammography screening rate increased to 
36.89% in 2006-2007 and 38.63% in 2007-2008.  Though higher than the 1.19% repeat 
mammogram rate observed with the original criteria used in the study (one mammogram every 
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10-14 months), the rate for screening with the new criteria (one mammogram every two years) 
still falls short of the rate reported by Weir et al. (2011).  Considering that major national 
organizations recommend mammography once every year, the original criteria used in our study 
falls in line with these recommendations, and therefore should be considered for policy 
implications.  The strikingly low rate of routine mammography screening obtained in this study 
highlights the urgent need of interventions aimed at increasing the use of mammography 
screening among women enrolled in Medicaid. 
Interesting results emerged from the multivariable analyses conducted to determine 
factors associated with repeat mammography screening.  Women in the age group 40-49 years 
were less likely to receive repeat mammography screening as compared to those in the age group 
50-64 years.  A likely reason for this finding could be the inconsistency in the mammography 
screening guidelines for women aged 40-49 years.  At the time of the study period, ACS, ACR, 
and ACOG recommended annual mammography screening whereas NCI and USPSTF 
recommended screening every 1-2 years in women aged 40-49 years (Feig, 2005).  On the other 
hand, annual mammography screening was universally recommended by all the major 
organizations for women aged 50 years or more at the time of the study period (Feig, 2005).  In 
the recent times, increasing evidence has accrued supporting the use of annual mammography 
screening in women aged 40-49 years (Gierisch ete al., 2009, Hellquist et al., 2010).  Currently, 
most of the major medical organizations recommend annual mammography screening in women 
beginning at age 40.  Ethnic minorities including Hispanic or Latino, Asian, and Native 
Hawaiian or other Pacific Islander had higher odds of receiving repeat mammography screening 
as compared to whites.  Other studies involving Medicaid enrollees have reported similar results 
(Dubard et al., 2009, Weir et al., 2011).  In their study involving enrollees of the Massachusetts 
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Medicaid managed care system, Weir et al. (2011) found that Hispanics and others (American 
Indians, Asian/Pacific Islanders, and other race) were 40% and 61%, more likely, respectively, to 
receive routine mammography screening as compared to whites.  It is possible that factors such 
as cultural influences and beliefs about preventive healthcare among minority women contribute 
towards their higher mammography screening rate.   
Number of outpatient visits during the study period was positively associated with the 
receipt of repeat mammography screening.  Similar results were reported by Barr et al. (2001) in 
their study involving women enrolled in a New York health maintenance organization.  In their 
study, women with 1-5 visits and 6 or more visits to primary care physicians during the study 
period of 2 years were 3.20 times and 4.30 times, more likely, respectively to receive regular 
mammography screening as compared to those with no visits.  The likely reason for the positive 
association between number of outpatient visits and repeat mammography screening observed in 
our study could be the increased likelihood of receiving a recommendation for mammography 
screening, one of the most influential factors affecting mammography screening, during 
outpatient visits (Miller et al., 2012).  Further, it is likely that regular exposure to mammography 
screening promotional campaigns, which are highly prevalent in physician offices and outpatient 
centers, positively affects the mammography screening behaviors of the patients.  Number of 
emergency room visits during the study period was negatively associated with receipt of repeat 
mammography screening.  The use of emergency rooms is generally indicative of individual’s 
tendency not to seek routine care, which is likely to be translated to poor preventive health 
behaviors.  Considering the higher routine mammography screening rates among recipients with 
regular healthcare use, interventions aimed at increasing the regular use of mammography 
screening should be targeted towards recipients who do not routinely seek healthcare.  
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Interventions such as mailed brochures emphasizing the susceptibility of these individuals 
towards breast cancer, health consequences of breast cancer, and benefits of routine 
mammography screening could be used to promote regular mammography screening.  
A positive association was observed between hormone replacement therapy and repeat 
mammography screening.  Similar finding has been observed in previous studies (Bobo et al., 
2004, Rahman et al., 2004).  The likely reason for higher rates of repeat mammography 
screening observed among women on hormone replacement therapy could be the elevated risk of 
breast cancer among women receiving hormone replacement therapy as established in the highly 
publicized Women’s Health Initiative trial in 2002 (Rossouw et al., 2002, Chlebowski et al., 
2009).  Consistent with the prior literature, receipt of routine mammography screening was 
found to be positively associated with routine cervical cancer screening.  While it could not be 
ascertained in our study on account of limitations in the data, other studies have found that other 
preventive health behaviors including colorectal cancer screening tests, influenza shots, 
cholesterol tests, blood glucose exams, and gynecologic exams positively impact regular 
mammography screening (Phillips et al., 1998, Cummings et al., 2000, Rauscher et al. 2005, 
Rosenberg et al., 2005, Wu et al., 2007).  These findings suggest the role played by preventive 
health behaviors in breast cancer screening.  Healthcare providers should recommend and 
reiterate the importance of routine mammography screening while women seek other preventive 
health behaviors.  In terms of association between neighborhood factors and repeat 
mammography screening, we observed statistically insignificant results for the most part.   
Few limitations in our study need to be addressed.   Administrative claims data can be 
subject to coding errors, which can affect the study results.  Beneficiaries enrolled in both 
Medicare and Medicaid were excluded from the study since complete information about their 
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healthcare utilization was not available in MAX files.  Hence the results of this study are not 
representative of the entire Medicaid population in the US.  Information about free or unbilled 
mammograms provided by clinics, hospitals, or healthcare programs was not available in the 
MAX files, which might have led to underestimation of the actual screening rates in the 
Medicaid population.  Psychological factors affecting use of mammography such as perceived 
risk and severity of breast cancer, and views about benefits of mammography and other factors 
such as recommendation from a physician and family history of breast cancer were not included 
in the study due to lack of information in the MAX files.  The Area Resource File data for the 
number of mammography screening facilities per 10,000 women in the county do not correspond 
to the study period.  The results of this study should be interpreted taking these limitations into 
consideration.  
The current study determined the prevalence of repeat mammography screening and the 
associated factors in the Medicaid population.  Only ~1.2% of the women aged 40-64 years 
received repeat mammograms during the study period in accordance with the established 
guidelines.  The repeat mammography screening rates were higher in women aged 50-64 years 
and those belonging to ethnic minorities as compared to women aged 40-49 years and whites 
respectively.  Number of outpatient visits during the study period was positively associated, 
whereas number of emergency room visits during the study period was negatively associated 
with receipt of repeat mammography screening.  Use of hormone replacement therapy and 
routine cervical cancer screening were positively associated with repeat mammography 
screening.  The results for the association between neighborhood healthcare access-related and 
sociodemographic variables and receipt of repeat mammography screening were statistically 
insignificant for the most part.  Policy makers could use the study findings to design 
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interventions aimed at increasing the routine mammography screening rates in the Medicaid 
population.  
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CHAPTER 5 
SUMMARY AND CONCLUSIONS 
Study Summary 
Breast cancer has changed from its initial perception of being a death sentence.  With the 
advances in breast cancer clinical research over the years, the survival rates have improved 
vastly.  The five-year breast cancer survival rates have increased from ~40% in 1954 to ~89% in 
2012, whereas the ten-year breast cancer survival rates have increased from ~25% in 1954 to 
~82% in 2012 (American Cancer Society).  Breast cancer is now considered as a chronic 
condition and is generally managed with a combination of surgical treatments to remove the 
tumor and systemic treatments to prevent tumor recurrence.  The current project examined three 
key issues of importance for effective breast cancer management in the economically 
underprivileged Medicaid population.  Medicaid is one of the largest healthcare payer systems in 
the United States (US) covering over 60 million low-income individuals.  
 The first study in this project determined the healthcare utilization and costs associated 
with breast cancer in the women Medicaid population using the data from the 2006-2008 
Medicaid analytic extract (MAX) files for 39 states in the US.  Information about healthcare use 
and costs attributable to a disease is useful to program planners in allocating resources for the 
treatment of patients.  Prior study in this area had used state-specific data (Khanna et al. 2011) 
and hence with the use of national Medicaid data, the current study makes a significant 
contribution to literature.  Breast cancer-related healthcare use in the form of inpatient, 
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outpatient, and emergency room (ER) visits was determined among women with breast cancer.  
Outpatient visits were found to be responsible for more than 95% of the breast cancer-related 
healthcare use.  All-cause healthcare use and costs were compared between women with breast 
cancer and a matched control group of women without breast cancer.  It was found that all-cause 
inpatient, outpatient, and ER visits and total all-cause costs were significantly higher among 
women with breast cancer as compared to those without breast cancer.  The findings of this study 
are reflective of the significant healthcare burden associated with breast cancer in the Medicaid 
population.   
 The second study in this project determined the impact of pre-existing mental illnesses on 
guideline-consistent breast cancer treatment and breast cancer-related healthcare utilization 
among Medicaid enrollees diagnosed with breast cancer.  It has been reported in previous studies 
that considerable proportion of women with breast cancer does not receive treatment consistent 
with the established guidelines (Bloom et al., 2004, Landercasper et al., 2006, Foley et al., 2007, 
Worthington et al., 2008, Iyengar et al., 2010, Shirvani et al., 2011).  An understanding of factors 
affecting guideline-consistent breast cancer treatment is necessary to increase use of guideline-
consistent breast cancer treatment in breast cancer patients.  The current study added to literature 
concerning factors affecting guideline-consistent breast cancer treatment by determining the 
association between pre-existing mental illnesses and guideline-consistent breast cancer 
treatment (breast conserving surgery followed by radiation therapy or total mastectomy with or 
without radiation therapy for Stage I and II breast cancers and chemotherapy for Stages III and 
IV breast cancers).  In addition, the impact of pre-existing mental illnesses on breast cancer-
related healthcare use (inpatient, outpatient, and ER visits) was determined.  Data from the 2006-
2008 Medicaid analytic extract (MAX) files for 39 states were used in this study.  Negative 
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association was observed between pre-existing mental illnesses and guideline-consistent breast 
cancer treatment.  Also, lower number of breast cancer-related outpatient visits were observed 
among women with breast cancer with pre-existing mental illnesses as compared to those 
without pre-existing mental illnesses.  The results of this study reflect the treatment disparities 
experienced by women with breast cancer with pre-existing mental illnesses as compared to 
those without any pre-existing mental illnesses. 
 The third study in this project determined the prevalence of repeat mammography 
screening and the associated factors in the national Medicaid population.  Routine 
mammography screening has been associated with early detection of breast cancer and increased 
survival.  Prior studies in this regard involved women belonging to a single state enrolled in 
either managed care or fee-for-service system (Weir et al., 2011, Bhanegaonkar et al., 2012).  
The data sources used in this study included the 2006-2008 MAX files for 39 states and the 
2010-2011 Area Resource File.  Roughly 1.2% of the eligible women were found to have 
received repeat mammograms during the study period.  Impact of various recipient and 
neighborhood characteristics on repeat mammography screening was determined.  In general, the 
repeat mammography screening rates were found to be higher among women belonging to ethnic 
minorities as compared to white women.  Age, number of outpatient visits during the study 
period, use of hormone replacement therapy, and routine cervical cancer screening were 
positively associated, whereas number of ER visits during the study period were negatively 
associated with receipt of repeat mammography screening.  The findings of this study could be 
useful for designing strategies aimed at improving repeat mammography screening rates in the 
women Medicaid population. 
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Study significance  
Significance of study 1: Healthcare burden associated with breast cancer in the Medicaid 
program 
An understanding of the healthcare burden associated with breast cancer in the Medicaid 
population could be helpful for policy-makers for allocation of resources for breast cancer 
management in the Medicaid population.  Information about current estimates of the breast 
cancer burden in the Medicaid population is crucial considering the Medicaid expansion under 
Patient Protection and Affordable Care Act (PPACA), due to which alterations in Medicaid 
financing are expected in the coming years (Kaiser Family Foundation).  The significant 
healthcare burden of breast cancer in the Medicaid population demonstrated in this study could 
trigger actions aimed at reducing the morbidity and mortality associated with breast cancer from 
the Medicaid policy-makers such as interventions aimed at improving breast cancer screening 
rates and increasing awareness about breast cancer and its risk factors.  The estimates of breast 
cancer-related healthcare utilization and costs obtained in this study can act as a benchmark on 
which the effectiveness of future healthcare interventions can be evaluated.    
 
Significance of study 2: Impact of pre-existing mental illnesses on receipt of guideline-consistent 
breast cancer treatment and breast cancer-related healthcare utilization  
An understanding of the association between pre-existing mental illnesses and receipt of 
guideline-consistent breast cancer treatment and breast cancer-related healthcare utilization could 
be of significant aid to policy-makers in developing strategies oriented towards ensuring 
adequate treatment of breast cancer patients.  The negative association between pre-existing 
mental illness and guideline-consistent breast cancer treatment and breast cancer-related 
 121 
 
healthcare use observed in this study indicates the need of more focused care of breast cancer 
patients with pre-existing mental illnesses.  Strategies such as physician counseling, healthcare 
skills training, peer-led counseling and help in accessing healthcare, and support from family 
members have been found to improve healthcare in individuals with mental illnesses and could 
become the standard of care in these individuals (Lawrence and Kisely, 2010).  Some mental 
illnesses such as depression can go undetected.  Therefore, screening for such illnesses could 
become a crucial aspect of breast cancer management.  Findings from this study could also 
encourage important cancer organizations such as American Society of Clinical Oncology 
(ASCO) and National Comprehensive Cancer Network (NCCN) to develop separate guidelines 
for management of breast cancer in patients with mental illnesses.  Considering the fact that the 
prevalence of mental illnesses among Medicaid enrollees is as high as 48% (Adelmann, 2003), 
the findings of this study are of significant relevance to the Medicaid policy-makers. 
 
Significance of study 3: Factors associated with repeat mammography screening among women 
enrolled in Medicaid 
Regular mammography screening has been found to be associated with earlier detection of breast 
cancer and improved survival as opposed to irregular or no mammography screening (Freedman 
et al., 2003, Moss et al., 2006, Hellquist et al., 2010).  Information about rates of repeat 
mammography screening obtained in the Medicaid population can help the policymakers in 
setting new goals for mammography screening in the Medicaid population.  Information about 
the current repeat mammography screening rates can also act as a benchmark on which the 
effectiveness of future interventions can be evaluated.  Information about factors affecting repeat 
mammography screening among Medicaid enrollees obtained in this study can help the policy-
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makers in planning and designing interventions aimed at increasing the repeat mammography 
screening rates in the Medicaid population.   
 
Limitations 
The limitations specific to each of the three studies in this project have been discussed in detail 
previously.  However, a summary of the overall limitations has been discussed below.  Coding 
errors are possible while processing of administrative claims, which could have impacted the 
results of this project.  The MAX data for some of the states were not available at the time of the 
study and hence findings of this project are not generalizable to the entire Medicaid population in 
the US.  Further, dual-eligibles, i.e., recipients enrolled in Medicaid and Medicare, were not 
included in the project since Medicare is the primary payer for these individuals and complete 
information about their medical care is not contained in the MAX files.  Hence the results 
obtained from this project are not representative of the Medicaid population belonging to the 39 
states considered in this study.  Details about the specialty of the physician providers were not 
available in the MAX files, due to which certain variables concerning physician specialty could 
not be included in this project.  Details such as the date of cancer diagnosis, stage of cancer at 
diagnosis, and the clinical characteristics of cancer including the hormone receptor, lymph node, 
and Human Epidermal Growth Factor Receptor 2 status were not available in the MAX files.  
Therefore, in study 1, it was not possible to distinguish between newly diagnosed and prevalent 
cases of breast cancer and compare the breast cancer-related healthcare use among different 
demographic sections of the population.  In study 2, for the same reason, the newly diagnosed 
cases of breast cancer and the cancer stage at diagnosis were identified using established 
algorithms developed by Solin et al. (1994) and Yuen et al. (2011).  Though these algorithms 
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have been found to have favorable measurement properties in different patient populations, they 
have not been validated in the Medicaid population.  Further, some of the established breast 
cancer treatment guidelines, including use of chemotherapy for lymph node-positive breast 
cancer, endocrine therapies for estrogen receptor-positive cancers, and tissue-targeted therapies 
for Human Epidermal Growth Factor Receptor 2-positive breast cancer, were not considered 
while determining guideline-consistent breast cancer treatment.  Details about the costs 
associated with each encounter record were not available for the Medicaid managed care 
enrollees.  Hence, analyses concerning breast cancer-specific costs could not be incorporated in 
this project.    
 
Directions for future research 
Considering the unavailability of the information concerning clinical characteristics of the cancer 
in the MAX files, future studies could link data from state tumor registries and the MAX data to 
answer certain important questions concerning breast cancer in the Medicaid population.  Breast 
cancer-related healthcare use by phase and stage of breast cancer could be studied longitudinally 
among Medicaid enrollees.  The tumor registry-linked Medicaid administrative claims data will 
make it possible to exhaustively define guideline-consistent breast cancer treatment based on 
hormone receptor and lymph node status of the tumor.  It will be interesting to see if the negative 
association between and pre-existing mental illnesses and guideline-consistent breast consistent 
treatment observed in this study holds true in that context as well.  Future studies could evaluate 
the effectiveness of various healthcare interventions aimed at improving breast cancer treatment 
in breast cancer patients with pre-existing mental illnesses.  Survey research techniques could be 
used to understand the impact of psychological factors such as perceived risk of breast cancer 
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and views about benefits of mammography and other factors such as recommendation from a 
physician and family history of breast cancer on routine mammography screening in the 
Medicaid population in future studies.  
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Appendix 1. Yuen’s algorithm for breast cancer staging 
American Joint Committee on 
Cancer breast cancer stage 
International Classification for Diseases, ninth revision, 
clinical modification codes 
0 233.0 
I 233.0 and 174.0-174.9 
II 233.0, 174.0-174.9, and 196.3 
III 233.0, 174.0-174.9, 196.3, 196.0, and 198.2 
IV 
233.0, 174.0-174.9, 196.3, 196.0, 198.2, 196.1-196.2, 196.5-
196.6, 196.8-196.9, 197.0-197.8, 198.0-198.1, 198.3-198.7, 
and 198.81-198.82. 
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